Lipids suitable for nucleic acid delivery

Abstract

The present invention provides lipids and lipid nanoparticle formulations that contain these lipids alone or in combination with other lipids.These lipid nanoparticles can be formulated with nucleic acid to facilitate intracellular delivery of nucleic acid in both in vitro and therapeutic applications.The present invention also provides methods for chemical synthesis of these lipids, methods for preparation of lipid nanoparticles, and methods for formulation with nucleic acid.

Description

[Technical Field]

[0001] The present invention provides lipids, and lipid nanoparticle formulations comprising these lipids alone or in combination with other lipids. These lipid nanoparticles may be formulated together with nucleic acids for the purpose of promoting intracellular delivery of nucleic acids in both in vitro and in vivo therapeutic applications. The present invention also provides methods for the chemical synthesis of these lipids, methods for preparing lipid nanoparticles, and methods for formulation with nucleic acids. [Background technology]

[0002] Therapeutic nucleic acids, including small interfering RNAs (siRNAs), microRNAs (miRNAs), antisense oligonucleotides, messenger RNAs (mRNAs), ribozymes, pDNAs, and immunostimulatory nucleic acids, act through various mechanisms. Certain proteins can be downregulated by RNA interference mediated by siRNA or miRNA (RNAi). Hematopoietic cells, particularly leukocytes and primary T lymphocytes and B cells, are generally known to be difficult to transform with small interfering RNAs (siRNAs). Modulating the function of immune cells, such as T cells and B cells, by downregulating specific genes using RNA interference (RNAi) holds immense potential for improving targeted therapies for many immune-related disorders, including cancer, inflammation, autoimmunity, and viral infections. The therapeutic applications of RNAi are extremely broad because siRNA and miRNA constructs can be synthesized for any creotide sequence targeting a target protein. To date, siRNA constructs have demonstrated the ability to specifically suppress target proteins in both in vitro and in vivo models. These are currently being evaluated in clinical trials.

[0003] Messenger RNA (mRNA) is a family of large RNA molecules that carry genetic information from DNA to ribosomes. Some nucleic acids, such as mRNA or plasmids, can be used to express specific cell products. Such nucleic acids may be useful in treating diseases associated with protein or enzyme deficiencies. However, many problems exist with nucleic acids in therapeutic contexts. One of the main problems with therapeutic nucleic acids is the stability of nucleotide bonds via phosphodiesters and their sensitivity to nucleases. Apart from this issue, these nucleic acids have limited ability to cross the cell membrane.

[0004] Various lipids, such as cationic lipids, have proven to be excellent carriers of nucleic acids for treating various diseases in gene therapy applications. Lipid nanoparticles formed from cationic lipids and other copolymers (such as cholesterol, DSPCs, and PEGylated lipids) encapsulate oligonucleotides, protecting them from degradation and promoting their uptake into cells.

[0005] WO2018087753 has the structure: -W-(T=O) m -X-(CH2) z We disclose cationic lipids comprising a functional group represented by -Y, where X and Y are independently O, N, or NH, and X and Y cannot both be O; W is bonded, O, NH, or S; T is C or S; m is 0 or 1; and z is 0 or 2, and the functional group is linked to at least one saturated or unsaturated fatty acid residue.

[0006] However, there is still a need in the art for suitable and efficient delivery platforms for oligonucleotide delivery. [Overview of the project]

[0007] The present invention relates to novel lipids that can be used in the preparation of lipid nanoparticles. These lipid nanoparticles protect nucleic acids from degradation, removal from circulation, and intracellular release. Further, lipid nanoparticles encapsulating nucleic acids are advantageously well-tolerated and provide an appropriate therapeutic index, such that treatment of patients at an effective dose of the nucleic acid is not associated with unacceptable toxicity and / or risk to the patient. The present invention also provides methods for the chemical synthesis of these lipids, methods for the preparation of lipid nanoparticles, and methods for formulation with nucleic acids.

[0008] In some embodiments, the present invention relates to novel lipids and formulations of such lipids having siRNA and pDNA. These lipid nanoparticles (LNPs) were further characterized by DLS and evaluated for their in vitro activity in various cancer cell lines.

[0009] According to some embodiments, chemical formula (II):

Chemical formula

[0010] According to several embodiments, R 1 is OH, C 2~3 alkyl-OH, and C 8~14 Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment of the present invention.

[0011] According to several embodiments, R 12 C 9~15 Alkenil, C 5~11 Alkyl, C 3~6 Alkyl-CO2-C 0~2 Alkylene-N(C) 2~8 Selected from the group consisting of alkyl)2. Each possibility represents a distinct embodiment of the present invention. The expression "Each L is selected from a group consisting of ~" is R 14 but, [ka] It is fine to be that way, Therefore, two distinct substituents L appear in the structure of chemical formula (II) (i.e., one L in the main part of the chemical formula, and R 14 It should be understood that this refers to the second L) state. In such a case, these substituents L, L a , X a and L b It is intended that each of these may be independently selected from the corresponding select group of a suitable embodiment. In other words, if two Ls appear, the substituent L a , X a and L b The two sets may be the same or they may be different.

[0012] According to several embodiments, R 13 These are OH, CH2-OH, and C 4~12 Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment of the present invention.

[0013] According to several embodiments, R 14 C 9~15 Alkenil, C 1~9 Alkyl and [ka] A selection is made from the group consisting of the following. Each possibility represents a distinct embodiment of the present invention.

[0014] According to several embodiments, X a -O2C- and -CO2-C 2~4 Selected from the group consisting of alkylene-O2C-. According to some embodiments, L a C 2~3 Alkylene and C 6~11 Selected from the group consisting of alkylenes. According to several embodiments, L b C 1~3 Alkylene and C 4~12 Selected from the group consisting of alkylenes.

[0015] According to several embodiments, the lipid is selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL3c-1, DSL2-1, DSL2-2, DSL2-49, DSL2-50, DSL4-1, and DSL4-2. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the lipid is selected from the group consisting of DSL1-3 and DSL2-50.

[0016] The chemical structures of each specific compound are described in detail in the “Exemplary Compounds” section and claims below.

[0017] According to several embodiments, chemical formula (I): [ka] This provides lipids represented by the structure (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof), Here L is L a -X a -L b and; X a -O2C-, -O-, -CO2-L c -O2C-, -O2C-L c -CO2-, -CO2-L c -CO2-, L c -CO2-, -L c Selected from the group consisting of -O2C-, -CO2-NH-, and -CO-NH-; L a C 4~20 Alkilen, C 4~20 Alkenylene and C 0~4 Selected from the group consisting of alkylenes; L b C 4~20 Alkilen, C 4~20 Alkenylene and C 0~4 Selected from the group consisting of alkylenes; L c C 1~6Alkylene-(O-C 1~6 alkylene) f -, C 2~6 alkenylene-(O-C 1~6 alkylene) g -, C 1~6 alkylene-S-C 1~6 alkylene, C 1~6 alkylene-S-S-C 1~6 alkylene, C 0~4 alkylene-aryl-C 0~4 alkylene, and C 1~4 selected from the group consisting of alkylene; each of f and g is 0, 1, 2, 3, 4 or 5; R 1 is C 0~10 alkylene-Y a , C 2~6 alkenylene-Y a , C 1~4 alkyl, C 5~25 alkyl, C 5~25 alkenyl, C 5~25 alkynyl, C 5~15 alkylene-CO2-C 5~15 alkyl, C 5~15 alkylene-CO2-C 5~15 alkenyl, C 5~15 alkylene-O2C-C 5~15 alkyl, C 5~15 alkylene-O2C-C 5~15 alkenyl, C 5~15 alkenylene-CO2-C 5~15 alkyl, C 5~15 alkenylene-CO2-C 5~15 alkenyl, C 5~15 alkenylene-O2C-C 5~15 alkyl, and C 5~15 alkenylene-O2C-C 5~15 selected from the group consisting of alkenyl; R 2 is C 5~25 alkyl, C 5~25 alkenyl, C 5~25 alkynyl, C 5~15 alkylene-CO2-C 5~15 alkyl, C 5~15Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-CH2CH2OCH2CH2-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Selected from the group consisting of alkylene-CO2H; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 0~6 Alkilen-Y d , C 2~6 Alkenirene-Y d , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; R 5 C 1~4 Alkyl, C 0~10 Alkylene-OH, C 0~10 Selected from the group consisting of alkylenes and halogens; R 6 C 5~25 Alkyl, C 5~25 Selected from a group consisting of alkenils; Y a OY b , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, pyrrolidinyl, piperidinyl, piperazinyl, SH, NMe2, NMe3 + , and NH-Y b Selected from the group consisting of; Y b H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl-Y c CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl; Y c The group is selected from H, NH2, NH(CH3), N(CH3)2, pyrrolidinylpiperidinyl, and piperazinyl, and pyrrolidinylpiperidinyl and piperazinyl are each optionally C 1~4 Substituted with alkyl; Y d OY e , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, SH, pyrrolidinyl, piperidinylpiperazinyl, NMe2, NMe3 + , and NH-Y e Selected from the group consisting of; Y e H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl-Y f CO-aryl, SO3H, SO3-(C1~4 Selected from the group consisting of alkyl and SO3-aryl; and Y f The group is selected from H, NH2, NH(CH3), N(CH3)2, pyrrolidinylpiperidinyl, and piperazinyl, and pyrrolidinylpiperidinyl and piperazinyl are each optionally C 1~4 It is substituted with an alkyl group.

[0018] L c C 1~6 Alkylene-(OC 1~6 Alkilen) f - and if f is 0, L c is C 1~6 Alkylene- and L c C 2~6 Alkenylene-(OC 1~6 Alkilen) g - and if g is 0, L c is C 2~6 It will be understood that it is an alkenylene. Similarly, C0 alkylene (for example, L a C as an option 0~4 The description in alkylenes would be understood to mean that this is absent, leaving a single bond between the preceding and following parts. One example is the L of compound DSL2-1. a This is described later as an absence (see the section on exemplary compounds).

[0019] According to several embodiments, R 2 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Selected from the group consisting of alkylene-CO2H; and R 4 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6Selected from the group consisting of

[0020] According to several embodiments, X a -O2C-, -O-, -CO2-L c -O2C-, -O2C-L c -CO2-, -L c Selected from the group consisting of -O2C-, -CO2-NH-, and -CO-NH-; L a C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L b C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L c C 1~6 Alkylene-OC 1~6 Alkylene-, C 1~6 Alkylene-SSC 1~6 Alkylene and C 1~4 Selected from the group consisting of alkylenes; R 1 C 0~10 Alkilen-Y a , C 1~4 Alkyl, and C 5~25 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C)5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2 and C 5~15 Selected from the group consisting of alkylene-CO2H; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 0~6 Alkilen-Y d , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; R 5 C 1~4 Alkyl, C 0~10 Alkylene-OH, and C 0~10 Selected from the group consisting of alkylenes and halogens; R 6 C 5~25 Alkyl and C 5~25 Selected from a group consisting of alkenils; Y a OY b Selected from the group consisting of halogens, PO3H2, NH2, and NMe2; Y b H, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH and CO-C 1~4 Alkyl-Y c Selected from the group consisting of; Y cIt is N(CH3)2; Y d OY e Selected from the group consisting of halogens and NH2; Y e H and CO-C 1~4 Alkyl-Y f Selected from the group consisting of; and Y f The group is selected from N(CH3)2 and piperazinyl, and piperazinyl is optionally C 1~4 It is substituted with an alkyl group.

[0021] According to several embodiments, X a These are -O2C- and -CO2-L c Selected from the group consisting of -O2C-; L a C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L b C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L c C 1~4 It is alkylene; R 1 C 0~10 Alkilen-Y a and C 5~25 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenyl and C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 5~25 Alkyl and C 0~6 Alkilen-Y d Selected from the group consisting of; R 4 C 5~25 Alkyl, C 5~25Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; R 5 C 0~10 It is alkylene-OH; R 6 C 5~25 It is an alkenil; Y a OY b and; Y b H is; Y d OY e and Y e H is H.

[0022] According to several embodiments, R 1 is OH or CH2CH2-R 21 and; R 2 It contains at least 6 carbon atoms, CH2CH2-R 22 It is represented by; R 3 H2CH2-R 23 and; R 4 It contains at least 6 carbon atoms and CH2CH2-R 24 It is represented by; R 1 , R 2 , R 3 , and R 4 None of them are H; Therefore, lipids are further classified by chemical formula (I'): [ka] Represented by the structure: R 21 C 0~8 Alkilen-Y a , C 2~4 Alkenirene-Y a , C 1~2 Alkyl, C3~25 Alkyl, C 5~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, and C 3~13 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; R 22 C 4~23 Alkyl, C 4~23 Alkenil, C 4~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C 3~13 Alkenylene-O2C-C 5~15 Alkenil, C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 0~13 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2, and C 3~13 Selected from the group consisting of alkylene-CO2H; R 23 H, C 3~23 Alkyl, C 3~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C 3~13 Alkenylene-O2C-C 5~15 Alkenil, C 0~4 Alkilen-Y d , C 0~4 Alkenirene-Y d , and C 1~2 Selected from the group consisting of alkyl groups; R 24 C 3~23 Alkyl, C 3~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C 3~13 Alkenylene-O2C-C 5~15 Alkenyl and C 3~13 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0023] According to several embodiments, R 22 CH2CH2-R 32 Represented by; R 24 CH2CH2-R 34 Represented by; Therefore, lipids have the chemical formula (I′′): [ka] Further represented by the structure; R 32 C 2~21 Alkyl, C 2~21 Alkenil, C 2~21 Alkinyl, C 1~11 Alkylene-CO2-C 5~15 Alkyl, C 1~11 Alkylene-CO2-C 5~15 Alkenil, C 1~11 Alkylene-O2C-C 5~15 Alkyl, C 1~11 Alkylene-O2C-C 5~15 Alkenil, C 2~11 Alkenylene-CO2-C 5~15 Alkyl, C 2~11 Alkenylene-CO2-C 5~15 Alkenil, C 2~11 Alkenylene-O2C-C 5~15 Alkyl, C 2~11Alkenylene-O2C-C 5~15 Alkenil, C 0~11 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 0~11 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 1~11 Selected from the group consisting of alkylene-CO2H; and R 34 C 1~21 Alkyl, C 2~21 Alkenil, C 2~21 Alkinyl, C 1~11 Alkylene-CO2-C 5~15 Alkyl, C 1~11 Alkylene-CO2-C 5~15 Alkenil, C 1~11 Alkylene-O2C-C 5~15 Alkyl, -C 1~11 Alkylene-O2C-C 5~15 Alkenil, C 2~11 Alkenylene-CO2-C 5~15 Alkyl, C 2~11 Alkenylene-CO2-C 5~15 Alkenil, C 2~11 Alkenylene-O2C-C 5~15 Alkyl, C 2~11 Alkenylene-O2C-C 5~15 Alkenyl and C 1~11 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0024] According to several embodiments, R32 CH2(CH2)6-R 42 Represented by; R 34 CH2(CH2)-R 44 Represented by; Therefore, lipids have the chemical formula (I′′′): [ka] Further represented by the structure; R 42 H, C 1~17 Alkyl, C 2~17 Alkenil, C 2~17 Alkinyl, C 0~7 Alkylene-CO2-C 5~15 Alkyl, C 0~7 Alkylene-CO2-C 5~15 Alkenil, C 0~7 Alkylene-O2C-C 5~15 Alkyl, C 0~7 Alkylene-O2C-C 5~15 Alkenil, C 2~7 Alkenylene-CO2-C 5~15 Alkyl, C 2~7 Alkenylene-CO2-C 5~15 Alkenil, C 2~7 Alkenylene-O2C-C 5~15 Alkyl, C 2~7 Alkenylene-O2C-C 5~15 Alkenil, C 0~11 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~7 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 0~7 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~7 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 0~7 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C0~7 Selected from the group consisting of alkylene-CO2H; and R 44 H, C 1~17 Alkyl, C 2~17 Alkenil, C 2~17 Alkinyl, C 0~7 Alkylene-CO2-C 5~15 Alkyl, C 0~7 Alkylene-CO2-C 5~15 Alkenil, C 0~7 Alkylene-O2C-C 5~15 Alkyl, C 0~7 Alkylene-O2C-C 5~15 Alkenil, C 2~7 Alkenylene-CO2-C 5~15 Alkyl, C 2~7 Alkenylene-CO2-C 5~15 Alkenil, C 2~7 Alkenylene-O2C-C 5~15 Alkyl, C 2~7 Alkenylene-O2C-C 5~15 Alkenyl and C 0~7 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0025] According to several embodiments, R 1 and R 2 It has a total of at least 9 carbon atoms, and R 3 and R 4 It has a total of at least 9 carbon atoms. According to some embodiments, L a and L b Each of them is C 0~4 Alkylene or C 4~20 It is alkylene and L a and L b At least one of them is C 3~15 It is an alkylene. a and L b Each of them is C 0~20 It is alkylene and L a and L bAt least one of them is C 3~15 It is an alkylene. a and L b Each of these is individually C 3~20 It is alkylene.

[0026] According to several embodiments, R 1 C 8~18 Alkyl, C 8~18 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Alkyl, C 1~3 Alkylene-OH, C 1~3 Alkylene-O-CH2CH2-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 2~12 Alkylene-CO2H, C 5~10 Alkylene-CO2-C 5~10 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl and LN(R3)-R4; R 3 H, C 8~18 Alkyl and C 8~18 Alkenil, C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; and R 4 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkenyls.

[0027] According to several embodiments, R 1 C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkenyls and LN(R3)-R4; R 3 C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; and R 4 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkenyls.

[0028] According to several embodiments, R 1 C 8~18 Alkyl, C 8~18 Alkenil; C 1~3 Alkylene-OH, C 1~3 Alkylene-O-CH2CH2-OH, C 1~3 Alkylene-Cl, C 1~3 Alkylene-NH2, OH, and C 1~3 Selected from the group consisting of alkylene-PO3H2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 2~12 Alkylene-CO2H, LN(R3)-R4, and C 5~10 Alkylene-CO2-C 5~10 Selected from a group consisting of alkenils; R 3 H, C 8~18 Alkyl and C 8~18 Selected from the group consisting of alkenyls; and R 4 C 8~18 Alkyl, C 8~18 Selected from the group consisting of alkenyls.

[0029] According to several embodiments, R 1 C 8~18 Alkyl and C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl groups; R 2 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl groups; R 3 H and C 8~18 Alkyl and C 8~18 Selected from the group consisting of alkenyls; and R 4 C 8~18 It is alkyl.

[0030] According to some embodiments, L is L 1 -X 1 -L 2 and; X 1 -O2C-, -CO2-L 3 -O2C-, -O2C-L 3 -CO2-, -CO2-L 3 -CO2-, L 3 -CO2- and L 3 Selected from the group consisting of -O2C-; L 1 and L 2 Each of them independently, C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 3 C1~6 Alkylene-(OC 1~6 Alkilen) n -, C 2~6 Alkenylene-(OC) 1~6 Alkilen) m -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of n and m is either 0, 1, 2, 3, 4, or 5; R 1 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Alkylene-O2C-C 5~15 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 0~6Alkylene-Y 1 C 2~6 Alkenylene-Y 1 and C 1~4 selected from the group consisting of alkyl; R 4 is C 5~25 alkyl, C 5~25 alkenyl, C 5~15 alkylene-CO2-C 5~15 alkyl, C 5~15 alkylene-CO2-C 5~15 alkenyl, C 5~15 alkylene-O2C-C 5~15 alkyl, C 5~15 alkylene-O2C-C 5~15 alkenyl, C 5~15 alkenylene-CO2-C 5~15 alkyl, C 5~15 alkenylene-CO2-C 5~15 alkenyl, C 5~15 alkenylene-O2C-C 5~15 alkyl and C 5~15 alkenylene-O2C-C 5~15 alkenyl selected from the group consisting of; each Y 1 is O-Y 2 halogen, PO3H2, PO3(C 1~4 alkyl)2, PO3H(C 1~4 alkyl), NH2, NMe2, and NH-Y 2 selected from the group consisting of; and Y 2 is H, C 1~4 alkyl, C 1~4 alkylene-OH, PO3H2, PO3(C 1~4 alkyl)2, PO3H(C 1~4 alkyl), CO-C 1~4 alkyl, CO-aryl, SO3H, SO3-(C 1~4 alkyl), and SO3-aryl selected from the group consisting of; or L is L 4 -X 2 -L 5 where; X 2is selected from the group consisting of -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 -O2C-, and -CO-NH-; L 4 is C 0~4 alkylene; L 5 is C 2~20 alkylene and C 4~20 alkenylene; L 6 is C 1~6 alkylene-(O-C 1~6 alkylene) j -, C 2~6 alkenylene-(O-C 1~6 alkylene) k -, C 1~6 alkylene-S-C 1~6 alkylene and C 1~6 alkylene-S-S-C 1~6 alkylene; each of j and k is 0, 1, 2, 3, 4 or 5; R 1 is C 0~10 alkylene-Y 3 , C 2~6 alkenylene-Y 3 , and C 1~4 alkyl; R 2 is C 5~25 alkyl, C 5~25 alkenyl, C 5~15 alkylene-CO2-C 5~15 alkyl, C 5~15 alkylene-CO2-C 5~15 alkenyl, C 5~15 alkylene-O2C-C 5~15 alkyl, C 5~15 alkylene-O2C-C 5~15 alkenyl, C 5~15 alkenylene-CO2-C 5~15 alkyl, C 5~15Alkenylene-CO2-C 5~15 Alkenyl, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl, C 5~15 Alkylene-CO2H, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C 5~25 Alkenyl)2, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C 1~12 Alkyl), and C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 selected from the group consisting of alkyl; R 3 is H, C 5~25 Alkyl, C 5~25 Alkenyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenyl, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenyl, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenyl, C 5~15 Alkenylene-O2C-C 5~15 Alkyl and C 5~15 Alkenylene-O2C-C 5~15 selected from the group consisting of alkenyl; R 4 is C 5~25 Alkyl, C 5~25 Alkenyl, C5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 Selected from the group consisting of; Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1~3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, CO-C 1~4 Alkyl-N(CH3)2,SO3H,SO3-(C 1~4 Alkyl), NMe2, CO-C 1~4 Selected from the group consisting of alkyl-NM2 and SO3-aryl; or L is L 7 -X 3 -L 8 and; X 3 -O2C-, -CO2-NH-, -CO2-L 9 -O2C-, -O2C-L9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-; L 7 C 0~4 It is alkylene; L 8 C 0~4 Alkylene or C 4~20 It is alkylene; L 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of h and i is either 0, 1, 2, 3, 4, or 5; R 1 C 5~25 Alkyl, C 5~25 Alkenyl and C 0~10 Alkylene-O-CO-C 1~4 Selected from the group consisting of alkyl-N(CH3)2; R 2 and R 4 Each of them independently, C 5~25 Alkyl and C 5~25 Selected from the group consisting of alkenyls; and R 3 H, C 5~25 Alkyl, and C 5~25 Selected from the group consisting of alkenyls.

[0031] According to some embodiments, L is L 1 -X 1 -L 2and; X 1 -O2C-, -CO2-L 3 -O2C-, -O2C-L 3 -CO2-, -CO2-L 3 -CO2-, L 3 -CO2- and L 3 Selected from the group consisting of -O2C-; L 1 and L 2 Each of them is C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 3 C 1~6 Alkylene-(OC 1~6 Alkilen) n -, C 2~6 Alkenylene-(OC 1~6 Alkilen) m -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of n and m is either 0, 1, 2, 3, 4, or 5; R 1 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Alkylene-O2C-C 5~15 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; Each Y 1 OY 2 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C1~4 Alkyl), NH2, NMe2, and NH-Y 2 Selected from the group consisting of; and Y 2 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. According to some embodiments, X 1 These are -O2C- and -CO2-L 3 Selected from the group consisting of -O2C-; L 1 and L 2 Each of them is C 5~15 It is alkylene; L 3 C 1~4 Alkilen- is; R 1 C 0~4 Alkilen-Y 1 and; R 2 C 9~20 Alkyl and C 9~20 Selected from a group consisting of alkenils; R 3 C 1~4 Alkilen-Y 1 and; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; and Each Y 1 It is OH.

[0032] Expression “Each Y 1 "is selected from a group consisting of ~" is R 1 However, C 0~6 Alkilen-Y1 or C 2~6 Alkenirene-Y 1 It is acceptable for it to be, and R 3 However, C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 It is understood to refer to a state in which Y is acceptable. 1 R 1 and R 3 If they appear in both, these substituents Y 1 Each of them is Y 1 This is intended to mean that they can be independently selected from the group. In other words, Y 1 R 1 and R 3 If they appear in both of these substituents Y 1 They may be the same, or they may be different.

[0033] According to some embodiments, L is L 1 -X 1 -L 2 and C 6~15 Alkylene-O2C-C 6~15 Alkilen, C 4~15 Alkylene-CO2-C 1~3 Alkylene-(OC 1~3 Alkilen) n -O2C-C 4~15 Alkylene and C 4~15 Alkylene-CO2-C 1~4 Alkylene-SSC 1~4 Alkylene-O2C-C 4~15 Selected from the group consisting of alkylenes; n is 0, 1, or 2.

[0034] According to several embodiments, R 1 CH2CH2PO3H2, CH2CH2Cl, CH2CH2OH, CH3, OH, and C 1~3 Selected from the group consisting of alkyl groups. According to several embodiments, R 2 C 8~16 Alkyl, C 8~20 Alkenyl and LN(R3 )-R 4 Selected from the group consisting of R. According to several embodiments, 2 R 4 It is the same as R 3 CH2CH2PO3H2, CH2CH2Cl, CH2CH2OH, CH3, OH, and C 1~3 Selected from the group consisting of alkyl groups. According to several embodiments, R 1 R 3 It is the same as R 4 C 8~16 Alkyl, C 8~20 Alkenyl and C 8~12 Alkylene-CO2-C 8~12 Selected from the group consisting of alkenyls.

[0035] According to some embodiments, L is L 4 -X 2 -L 5 and; X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 Selected from the group consisting of -O2C- and -CO-NH-; L 4 C 0~4 It is alkylene; L 5 C 2~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC1~6 Selected from the group consisting of alkylenes; Each of j and k is either 0, 1, 2, 3, 4, or 5; R 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Selected from the group consisting of alkyl groups; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4Selected from the group consisting of; and Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1~3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, CO-C 1~4 Alkyl-N(CH3)2,SO3H,SO3-(C 1~4 Alkyl), NMe2, CO-C 1~4 The group is selected from alkyl-NM2 and SO3-aryl compounds.

[0036] According to several embodiments, X 2 It is -O2C-; L 4 C 0~4 Alkylene or C 4~20 It is alkylene; L 5 C 4~20 It is alkylene; R 1 C 0~10 Alkilen-Y 3 and; R 2 C 5~25 Alkyl, C 5~25 Alkenyl and C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 5~25 It is alkyl; R 4 C 5~25 It is alkyl; Y 3 OY b and Y 4 H is H.

[0037] According to some embodiments, L is L 4 -X 2 -L 5 and; X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 Selected from the group consisting of -O2C- and -CO-NH-; L 4 C 0~4 It is alkylene; L 5 C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of j and k is either 0, 1, 2, 3, 4, or 5; R 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 Selected from the group consisting of; Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl compounds. According to several embodiments, L is -O2C-C 6~12 Alkilen, C 1~3 Alkylene-CO2-C 1~3 Alkylene-SSC 1~3 Alkylene-O2C-C 4~10 Alkilen, C 1~3 Alkylene-CO2-C 6~12 Alkilen, C 1~3 Alkylene-OC 1~3 Alkylene-O2C-C 6~12 Alkylene and C 1~3 Alkylene-NHCO-C 6~12 Selected from the group consisting of alkylenes. According to several embodiments, R 1 R is selected from the group consisting of CH2CH2OH, CH2CH2OCH2CH2OH, CH2CH2Cl, OH, CH2CH2PO3H2, and CH2CH2NH2. According to several embodiments, 2 C 8~16 Alkyl, C 8~20Alkenil, C 6~12 Alkylene-CO2-C 6~12 Alkenil, C 6~12 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of R. According to several embodiments, 3 H, C 6~16 Alkyl, and C 6~16 Selected from the group consisting of alkenyls. According to some embodiments, R 3 R 4 It is identical to the above. According to several embodiments, R 4 C 6~16 Alkyl, C 6~16 Selected from the group consisting of alkenyls.

[0038] According to some embodiments, L is L 7 -X 3 -L 8 and; X 3 -O2C-, -CO2-NH-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-; L 7 C 0~4 It is alkylene; L 8 C 0~4 Alkylene or C 4~20 It is alkylene; L 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of h and i is either 0, 1, 2, 3, 4, or 5; R 1 C 5~25 Alkyl, C 5~25 Alkenyl and C 0~10 Alkylene-O-CO-C 1~4 Selected from the group consisting of alkyl-N(CH3)2; R 2 and R 4 Each of them independently, C 5~25 Alkyl and C 5~25 Selected from the group consisting of alkenyls; and R 3 H, C 5~25 Alkyl, and C 5~25 Selected from the group consisting of alkenyls. According to some embodiments, X 3 It is -O2C-; L 7 C 0~4 It is alkylene; L 8 C 0~4 It is alkylene; R 1 C 5~25 Alkyl and R 1 , R 2 , R 3 and R 4 Each of them is C 5~25 It is alkyl.

[0039] According to some embodiments, L is L 7 -X 3 -L 8 and; X 3 -O2C-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-; L7 C 0~4 It is alkylene; L 8 C 0~4 It is alkylene; L 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of h and i is 0, 1, 2, 3, 4 or 5; and R 1 , R 2 and R 3 Each of them independently, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls; and R 4 H, C 5~25 Alkyl, C 5~25 Alkenil, C5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0040] According to some embodiments, L is C 1~4 Alkylene-CO2-C 1~4 Alkilen, C 1~4 Alkylene-CO2-,O2C-C 1~3 Alkylene-C6H4-C 0~4 Alkylene-CO2, C 1~4 Alkylene-OC 1~4 Alkylene-O2C-C 1~4 Alkilen, C 1~4 Alkylene-O2C-C 1~6 Alkylene-CO2-C 1~4 Alkylene, O2C-C 1~4 Alkylene-SSC 1~4 Alkylene-CO2 and O2C-C 1~6 Selected from the group consisting of alkylene-CO2.

[0041] According to several embodiments, R 1 C 8~15 Alkyl, C 8~20 Alkenyl and C 6~12 Alkylene-O2C-C 9~18 Selected from the group consisting of alkylenes. According to several embodiments, R 2 C 8~15 Alkyl, C 8~20Alkenyl and C 6~12 Alkylene-O2C-C 9~18 Selected from the group consisting of alkylenes.

[0042] According to several embodiments, R 3 C 8~15 Alkyl and C 8~20 Selected from the group consisting of alkenyls. According to some embodiments, R 4 H, C 8~15 Alkyl, and C 8~20 Selected from the group consisting of alkenyls. According to some embodiments, R 4 C 8~15 Alkyl and C 8~20 Selected from the group consisting of alkenyls.

[0043] According to several embodiments, R 1 , R 2 , R 3 , and R 4 At least two of them represent the same substituent. According to some embodiments, R 1 , R 2 , R 3 , and R 4 Each of these represents a different substituent.

[0044] According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DS L1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46 , DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL1-58, DSL1-59, DSL1-60, DSL3c-1, DSL3 c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7 and DSL3c-8, DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2-19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2- 26, DSL2-27, DSL2-28, DSL2-29, DSL2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DSL2-40, DSL2-41, DS L2-42, DSL2-43, DSL2-44, DSL2-45, DSL2-46, DSL2-47, DSL2-48, DSL2-49, DSL2-50, DSL2-51, DSL2-52, DSL2-53, DSL2-54, DSL2-55, DSL2-56, DSL2-57,The compounds are selected from the group consisting of DSL2-58, DSL2-59, DSL2-60, DSL2-61, DSL2-62, DSL2-63, DSL2-64, DSL2-65, DSL2-66, DSL2-67, DSL2-68, DSL2-69, DSL2-70, DSL2-71, DSL2-72, DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13, DSL4-14, and DSL4-15. The chemical structure of each specific compound is detailed in the "Exemplary Compounds" section and claims below.

[0045] According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1 -30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-4 5, DSL1-46, DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7 and DSL3c-8, DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, D SL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2-19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2-26, DSL2-27, DSL2-28, DSL2-29, DSL 2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DSL2-40, DSL2-41, DSL2-42, DSL2-43, DSL2-44, DSL2- 45, DSL2-46, DSL2-47, DSL2-48, DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13,The group is selected from DSL4-14 and DSL4-15. According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DSL Selected from the group consisting of 1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL2-55, DSL2-56, DSL2-57, DSL2-58, DSL2-59, DSL2-60, DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8. Then, according to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1 -37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1-48, DSL1-49,The group is selected from DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8. According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1 Selected from the group consisting of -31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1-48, DSL1-49, DSL1-50 and DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL1-58, DSL1-59, and DSL1-60. Then, according to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1 -23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DS L1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46,The lipids are selected from the group consisting of DSL1-47, DSL1-48, DSL1-49, DSL1-50, and DSL1-51, DSL1-52, DSL1-53, and DSL1-54. According to some embodiments, the lipids are selected from the group consisting of DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8. According to the process embodiment, the lipids are DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2- 18, DSL2-19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2-26, DSL2-27 , DSL2-28, DSL2-29, DSL2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DS L2-37, DSL2-38, DSL2-39, DSL2-40, DSL2-41, DSL2-42, DSL2-43, DSL2-44, DSL2-45, DSL2 -46, DSL2-47, DSL2-48, DSL2-49, DSL2-50, DSL2-51, DSL2-52, DSL2-53, DSL2-54, DSL2-55 The group is selected from DSL2-56, DSL2-57, DSL2-58, DSL2-59, DSL2-60, DSL2-61, DSL2-62, DSL2-63, DSL2-64, DSL2-65, DSL2-66, DSL2-67, DSL2-68, DSL2-69, DSL2-70, DSL2-71, and DSL2-72. According to the process embodiment, the lipids are DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2-19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2-26, DSL2-27,The group is selected from DSL2-28, DSL2-29, DSL2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DSL2-40, DSL2-41, DSL2-42, DSL2-43, DSL2-44, DSL2-45, DSL2-46, DSL2-47, and DSL2-48. According to several embodiments, the lipids are selected from the group consisting of DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13, DSL4-14, and DSL4-15. According to several embodiments, the lipids are selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL2-1, DSL2-2, DSL4-1, DSL4-2, DSL3c-1, DSL2-49, and DSL2-50. According to several embodiments, the lipids are selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL2-1, DSL2-2, DSL4-2, DSL3c-1, DSL2-49, and DSL2-50.

[0046] According to several embodiments, the present invention provides particles comprising the present lipid and membrane-stabilizing lipid. According to several embodiments, the particles comprise a membrane-stabilizing lipid and a lipid membrane containing the lipid.

[0047] According to several embodiments, the membrane-stabilizing lipid is selected from the group consisting of cholesterol, phospholipids, kephalins, sphingolipids, and glyceroglycolipids. According to several embodiments, the membrane-stabilizing lipid includes cholesterol. According to several embodiments, the particles further include one or more additional components selected from the group consisting of PEG lipid complexes, neutral lipids, and charged lipids. According to several embodiments, the additional component includes 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). According to several embodiments, the additional component includes 1,2-dimiristoyl-sn-glyceryl-methoxypolyethylene glycol (DMG-PEG). According to several embodiments, the particles include lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-dimiristoyl-sn-glyceryl-methoxypolyethylene glycol (DMG-PEG). According to several embodiments, the particles are conjugated to a targetable moiety.

[0048] According to several embodiments, the particles further comprise nucleic acids. According to several embodiments, the nucleic acids are encapsulated within lipid-containing particles. According to several embodiments, the nucleic acids are selected from the group consisting of small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA, circular RNA, and immunostimulatory nucleic acids.

[0049] According to some embodiments, the particles further contain a therapeutic agent. According to some embodiments, the therapeutic agent is encapsulated within lipid-containing particles.

[0050] According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein, an immunogenic fragment thereof, or a variant thereof. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein, an immunogenic fragment of SARS-CoV-2, or a variant of SARS-CoV-2. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein.

[0051] According to several embodiments, compositions comprising a plurality of particles as disclosed herein, and a pharmaceutically acceptable carrier, diluent, or additive are provided. According to several embodiments, the composition is a liposome composition.

[0052] The present invention provides a method for gene silencing, comprising the step of contacting cells with a composition of the present invention, according to several embodiments.

[0053] According to several embodiments, the present invention provides a method for gene silencing, comprising the step of contacting cells with a composition comprising a plurality of particles and a pharmaceutically acceptable carrier, diluent, or additive. According to several embodiments, the cells are cancer cells.

[0054] In other embodiments, the compositions of the present invention may be used as a delivery system for administering a therapeutic agent to a target site in the body. According to several embodiments, a method for administering a therapeutic agent is provided, the method comprising the steps of preparing a composition comprising the lipids and therapeutic agent of the present invention, and administering the composition to a subject requiring it.

[0055] According to several embodiments, the method further comprises encapsulating a therapeutic agent within lipid-containing particles. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein or an immunogenic fragment or variant thereof. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein or an immunogenic fragment or variant thereof. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein, an immunogenic fragment of SARS-CoV-2, or a SARS-CoV-2 variant. Each possibility represents a distinct embodiment of the present invention.

[0056] The lipids of the present invention can be used alone or in combination with other lipid components, such as neutral lipids, charged lipids, steroids (including, for example, sterols) and / or their analogues, and / or polymers, to form lipid nanoparticles for therapeutic agent delivery. In some cases, lipid nanoparticles are used to deliver nucleic acids for the treatment of various diseases or conditions, particularly leukocyte-related conditions (such as inflammation and / or insufficient protein deficiency).

[0057] Accordingly, according to several embodiments, the present invention relates to a method for treating leukocyte-related conditions, the method comprising the step of administering a composition of the present invention to a subject in need thereof. Leukocyte-related conditions may be selected from the group consisting of cancer, infection, autoimmune diseases, neurodegenerative diseases, and inflammation. According to several embodiments, a method for treating leukocyte-related conditions is provided, the method comprising the step of administering a composition comprising a plurality of particles of the present invention and a pharmaceutically acceptable carrier, diluent or additive to a subject in need thereof.

[0058] Further embodiments and the full scope of the present invention will become apparent from the detailed description provided herein. However, since various modifications and changes within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description, the detailed description and specific examples should be understood to be provided only as illustrations, while illustrating preferred embodiments of the invention. [Brief explanation of the drawing]

[0059] [Figure 1] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 2] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 3]The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 4] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 5] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 6]The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 7] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 8] The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 9]The following ¹H NMR spectra (A) and ESI-MS (B) are shown: DSL1-1 (Figures 1A and 1B); DSL1-2 (Figures 2A and 2B); DSL1-3 (Figures 3A and 3B); DSL1-4 (Figures 4A and 4B); DSL1-5 (Figures 5A and 5B); DSL2-1 (Figures 6A and 6B); DSL2-2 (Figures 7A and 7B); DSL4-1 (Figures 8A and 8B); DSL4-2 (Figures 9A and 9B), DSL3c-1 (Figure 9C is the ¹H NMR spectrum; and Figure 9D is the ESI-MS), and DSL1-50 (Figure 9E is the ¹H NMR spectrum; and Figure 9F is the ESI-MS). [Figure 10] The following transmission electron microscope (TEM) images are shown: LNPs prepared from ionizable lipids DSL1-1 (Figure 10A), DSL1-2 (Figure 10B), DSL1-5 (Figure 10C), DSL2-50 (Figure 10D), DSL1-3 (Figure 10E), DSL3c-1 (Figure 10F), or DSL2-49 (Figure 10G). The images relate to organs from mice after intravenous administration of lipids. The organs, in this order, are the lungs, liver, spleen, and kidneys (lungs at the top, kidneys at the bottom). [Figure 11-1] The following IVIS image shows organs from mice after intravenous administration of mLUC-LNP containing DSL1-1 (Figure 11A), DSL1-2 (Figure 11B), DSL1-5 (Figure 11C), DSL1-4 (Figure 11D), DSL1-3 (Figure 11E), DSL4-2 (Figure 11F), DSL3c-1 (Figure 11G), DSL2-2 (Figure 11H), DSL2-1 (Figure 11I), DSL2-49 (Figure 11J), or DSL2-50 (Figure 11K) as ionizable lipids. The organs are, in this order, the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). [Figure 11-2] The following IVIS images show organs from mice intravenously administered with either 1.5% (second and third panels) or 2.5% PEG (fourth and fifth panels) of DSL1-3 LNP, and organs from untreated mice (first from the left panel). The organs, in this order, are the lungs, liver, spleen, and kidneys (lungs at the top, and kidneys at the bottom). [Figure 11-3]IVIS images of organs from mice administered with LNPs along with either the copolymer DOPE or DSPC are shown. Figure 11M shows DSL1-4 LNPs with DOPE (left panel) or DSPC (right panel); Figure 11N shows DSL1-5 LNPs with DOPE (left panel) or DSPC (right panel); Figure 11O shows DSL2-2 LNPs with DOPE (left panel) or DSPC (right panel); and Figure 11P shows DSL2-50 LNPs with DOPE (left panel) or DSPC (right panel). The organs, in this order, are the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). [Figure 11-4] IVIS images of organs from mice administered LNP at different molar ratios are shown. The upper left shows DSL1-5 at a 30% molar ratio; the upper right shows DSL1-5 at a 40% molar ratio; the lower left shows DSL2-50 at a 30% molar ratio; and the lower right shows DSL2-50 at a 40% molar ratio. The organs, in this order, are the lungs, liver, spleen, and kidneys (lungs at the top, and kidneys at the bottom). [Figure 11-5] The images show IVIS images of organs from mice administered either intravenously (left panel) or intramuscularly (right panel) with mRNA-LNP composed of DSL2-50. In the left panel, the organs are, in this order, the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). In the right panel, the organs are, in this order, the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). [Figure 12] This bar graph shows the quantitative analysis of luciferase expression in the spleen and liver of mice after intravenous administration of LNPs including DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL2-1, DSL2-2, DSL4-2, DSL3c-1, DSL2-49, and DSL2-50. [Figure 13]This bar graph shows FACS analysis of tdTomato expression in untreated Ai9 mice (mock, dotted bar) or in peritoneal macrophages (Figure 13A) and splenocytes (Figure 13B) isolated from Ai9 mice after intravenous administration of mCRE-LNPs including DSL1-1 (black dots on a white background), DSL1-2 (white dots on a black background), or DSL1-3 (diagonal bar). [Figure 14] This bar graph shows FACS analysis of tdTomato expression in different types of immune cells isolated from the spleen of untreated Ai9 mice (mock) or Ai9 mice after intravenous administration of mCRE-LNPs containing DSL1-3. [Figure 15] This bar graph shows the quantitative analysis of tdTomato expression in the spleen (Figure 15A) and liver (Figure 15B) of Ai9 mice after intravenous administration of MC3 mCRE-LNP or DSL1-2 mCRE-LNP, compared to untreated mice (mock-ups). [Figure 16-1] Figure 16B shows an analysis of luciferase expression observed in IVIS images of organs from mice administered DSL2-50 LNPs containing prepared luciferase mRNA at day 0 (Figure 16A, left panel) and day 210 (Figure 16A, right panel). The organs are, in this order, the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). Figure 16B is a histogram analysis of luciferase expression in the lungs, liver, spleen, and kidneys of mice at day 0 (vertical bar pattern) or day 210 (checkerboard bar pattern). [Figure 16-2] Figure 16D shows an analysis of mCherry expression observed in IVIS images of mice administered with DSL-50 LNP containing mCherry mRNA on day 0 after preparation (Figure 16C, center panel), control (Figure 16C, left panel), and 90 days after preparation (Figure 16C, right panel). The organs in Figure 16C are, in this order, the lungs, liver, spleen, and kidneys (lungs at the top and kidneys at the bottom). Figure 16D is a histogram analysis of mCherry expression in the lungs, liver, spleen, and kidneys of mice, compared to the control (Mock, diagonal bars) on day 0 (dotted bars) or day 90 (horizontal bars). [Figure 17] It shows the in vivo safety analysis of mRNA-LNP (DSL2-50 or DSL1-3) after intravenous administration. At 12 hours and 24 hours later, blood was collected, and serum samples were analyzed for the levels of liver enzymes alkaline phosphatase (Alk Phos), serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT). [Figure 18] It shows the mRNA delivery ability of single LNP. Figure 18A shows the IVIS images of the livers of mice after treatment with DSL2-50 LNP (the two right columns) or the model lipid SM102 (the two left columns) encapsulating luciferase (mLuc, lower panel) or mCherry (upper panel). Figure 18B shows the histogram analysis of the expression of luciferase and mCherry in mouse livers. [Figure 19] The titers of SARS-CoV-2 spike-specific antibodies in the sera of mice treated with RBD-hFc mRNA encapsulated in DSL1-3, 2-2, 2-50 or Moderna SM102 were evaluated by ELISA (Figure 19A), showing the evaluation of mRNA-LNP for COVID-19 vaccine delivery in BALB / c mice. Figure 19B shows the ELISPOT assay for the evaluation of COVID-19-specific T cell responses in splenocytes. Circles represent markers before booster; triangles represent markers after booster. [Figure 20] The titers of SARS-CoV-2 spike-specific antibodies in the sera of mice treated with RBD-hFc mRNA encapsulated in DSL1-3, 2-2, 2-50 or Moderna SM102 were evaluated by ELISA (Figure 20A), showing the evaluation of mRNA-LNP for COVID-19 vaccine delivery in C57BL6 mice. Figure 20B shows the ELISPOT assay for the evaluation of COVID-19-specific T cell responses in splenocytes. Circles represent markers before booster; triangles represent markers after booster.

Mode for Carrying Out the Invention

[0060] The present invention is based on the discovery of lipids useful in preparing lipid nanoparticles for delivering active substances in vitro and in vivo. The lipids of the present invention are useful in the delivery of nucleic acids such as siRNA, miRNA and mRNA.

[0061] Lipids As contemplated herein, the present invention relates to a lipid having the chemical formula (I):

Chemical formula

[0062] According to some embodiments, L is L a -X a -L b It should be understood that when referring to L a -X a -L b the order of the substituents is limited only to that X a is in the center and is sandwiched by L a and L b It is not intended to mean that L a is attached to N(R 1 )R 2 and L b is attached to N(R 3 )R​​​​​​​​​​​​​​​​​​​​​​​According to several embodiments, X a -O2C-, -O-, -CO2-L c -O2C-, -O2C-L c -CO2-, -CO2-L c -CO2-, L c -CO2-, L c Selected from the group consisting of -O2C-, -CO2-NH-, and -CO-NH-. According to some embodiments, X a It is O2C-. According to several embodiments, X a is -CO2-L c It is -O2C- according to several embodiments, X a is -O2C-L c It is -CO2- according to several embodiments, X a is -CO2-L c It is -CO2- according to several embodiments, X a L c It is -CO2- according to several embodiments, X a L c It is -O2C- according to several embodiments, X a is -CO-NH-. According to some embodiments, X a It is -CO2-NH-.

[0064] According to several embodiments, L a C 4~20 Alkilen, C 4~20 Alkenylene and C 0~4 Selected from the group consisting of alkylenes. According to several embodiments, L a C 4~20 It is an alkylene. a C 4~10 It is an alkylene. a C 10~20 It is an alkylene. a C 4~20 It is an alkenylene. a C 4~10 It is an alkenylene.a C 10~20 It is an alkenylene. a C 0~4 It is alkylene.

[0065] According to several embodiments, L b C 4~20 Alkilen, C 4~20 Alkenylene and C 0~4 Selected from the group consisting of alkylenes. According to several embodiments, L b C 4~20 It is an alkylene. b C 4~10 It is an alkylene. b C 10~20 It is an alkylene. b C 4~20 It is an alkenylene. b C 4~10 It is an alkenylene. b C 10~20 It is an alkenylene. b C 0~4 It is alkylene.

[0066] According to several embodiments, L c C 1~6 Alkylene-(OC 1~6 Alkilen) f -, C 2~6 Alkenylene-(OC 1~6 Alkilen) g -, C 1~6 Alkilen-SC 1~6 Alkilen, C 1~6 Alkylene-SSC 1~6 Alkilen, C 0~4 Alkilen-aryl-C 0~4 Alkylene and C 1~4 Selected from the group consisting of alkylenes. According to several embodiments, L c C 1~6Alkylene-(OC 1~6 Alkilen) f - According to several embodiments, L c C 1~6 It is an alkylene. c C 2~6 Alkenylene-(OC 1~6 Alkilen) g - According to several embodiments, L c C 1~6 Alkilen-SC 1~6 It is an alkylene. c C 1~6 Alkylene-SSC 1~6 It is an alkylene. c C 1~4 Alkylene-SSC 1~4 It is an alkylene. c C 1~2 Alkylene-SSC 1~2 It is an alkylene. c C 0~4 Alkilen-aryl-C 0~4 It is an alkylene. c C 1~4 Alkilen-aryl-C 1~4 It is an alkylene. c C 0~2 Alkilen-aryl-C 0~2 It is an alkylene. c C 1~4 It is an alkylene. According to some embodiments, f and g are 0, 1, 2, 3, 4, or 5, respectively. According to some embodiments, f is 0, 1, or 2. According to some embodiments, f is 0. According to some embodiments, f is 1. According to some embodiments, g is 0, 1, or 2. According to some embodiments, g is 0. According to some embodiments, g is 1.

[0067] According to several embodiments, R 1 C 0~10 Alkilen-Y a , C 2~6 Alkenirene-Y a , C 1~4 Alkyl, C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R 1 C 0~10 Alkilen-Y a According to several embodiments, R 1 Y a According to several embodiments, R 1 C 1~2 Alkilen-Y a According to several embodiments, R 1 C 5~10 Alkilen-Y a According to several embodiments, R 1 C 2~6 Alkenirene-Y a According to several embodiments, R 1 C 1~4 It is alkyl. According to several embodiments, R 1 C 5~25 It is alkyl. According to several embodiments, R 1 C5~15 It is alkyl. According to several embodiments, R 1 C 12~25 It is alkyl. According to several embodiments, R 1 C 5~25 It is an alkenyl. According to several embodiments, R 1 C 5~10 It is an alkenyl. According to several embodiments, R 1 C 10~25 It is an alkenyl. According to several embodiments, R 1 C 5~15 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 1 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl. According to some embodiments, R 1 C 5~15 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 1 C 5~15 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 1 C 5~15 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 1 C 5~15 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 1 C 5~15 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 1 C 5~15 Alkenylene-O2C-C 5~15 It is Alkenil.

[0068] According to several embodiments, R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-CH2CH2OCH2CH2-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Selected from the group consisting of alkylene-CO2H.

[0069] According to several embodiments, R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 The group is selected from alkylene-CO2H and LN(R3)-R4.

[0070] According to several embodiments, R 2 C 5~25 It is alkyl. According to several embodiments, R 2 C 5~10 It is alkyl. According to several embodiments, R 2 C 10~18 It is alkyl. According to several embodiments, R 2 C 18~25 It is alkyl. According to several embodiments, R 2 C 5~25 It is an alkenyl. According to several embodiments, R 2 C 5~10 It is an alkenyl. According to several embodiments, R 2 C 10~18 It is an alkenyl. According to several embodiments, R 2 C 18~25 It is an alkenyl. According to several embodiments, R 2 C 5~15 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 2 C 5~15 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 2 C5~15 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 2 C 5~15 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 2 C 5~15 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 2 C 5~15 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 2 C 5~15 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 2 C 5~15 It is alkylene-CO2H, according to several embodiments, R 2 This is LN(R3)-R4.

[0071] According to several embodiments, R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 2 C 2~15 Alkylene-CO2-CH2CH2OCH2CH2-N(C) 1~12 It is alkyl)2. According to some embodiments, R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 It is alkyl. According to several embodiments, R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 It is alkenyl)2, according to some embodiments, R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl. According to several embodiments, R2 C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 It is alkyl(2).

[0072] According to several embodiments, R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 0~6 Alkilen-Y d , C 2~6 Alkenirene-Y d , and C 1~4 Selected from the group consisting of alkyl groups.

[0073] According to several embodiments, R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 0~6 Alkilen-Y a , C 2~6 Alkenirene-Y a , and C 1~4 Selected from the group consisting of alkyl groups. According to several embodiments, R 3 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 0~6 Alkilen-Y a , C 2~6 Alkenirene-Y a , and C 1~4 Selected from the group consisting of alkyl groups. According to several embodiments, R 3 H is H. According to some embodiments, R 3 C 5~25 It is alkyl. According to several embodiments, R 3 C 5~10 It is alkyl. According to several embodiments, R 3 C 10~18 It is alkyl. According to several embodiments, R 3 C18~25 It is alkyl. According to several embodiments, R 3 C 5~25 It is an alkenyl. According to several embodiments, R 3 C 5~10 It is an alkenyl. According to several embodiments, R 3 C 10~18 It is an alkenyl. According to several embodiments, R 3 C 18~25 It is an alkenyl. According to several embodiments, R 3 C 5~15 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 3 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 3 C 5~15 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 3 C 5~15 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 3 C 5~15 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 3 C 5~15 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 3 C 5~15 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 3 C 5~15 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 3 C 0~6 Alkilen-Y a According to several embodiments, R 3 C 0~6 Alkilen-Y d According to several embodiments, R 3 C2~6 Alkenirene-Y d According to several embodiments, R 3 C 0~10 Alkilen-Y a According to several embodiments, R 3 Y a According to several embodiments, R 3 Y d According to several embodiments, R 3 C 1~2 Alkilen-Y a According to several embodiments, R 3 C 2~6 Alkenirene-Y a According to several embodiments, R 3 C 1~4 It is alkyl. According to several embodiments, R 3 It is not H.

[0074] According to several embodiments, R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~25 Alkinyl, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0075] According to some embodiments, R 4 is C 5~25 alkyl, C 5~25 alkenyl, C 5~25 alkynyl, C 5~15 alkylene-CO2-C 5~15 alkyl, C 5~15 alkylene-CO2-C 5~15 alkenyl, C 5~15 alkylene-O2C-C 5~15 alkyl, C 5~15 alkylene-O2C-C 5~15 alkenyl, C 5~15 alkenylene-CO2-C 5~15 alkyl, C 5~15 alkenylene-CO2-C 5~15 alkenyl, C 5~15 alkenylene-O2C-C 5~15 alkyl, and C 5~15 alkenylene-O2C-C 5~15 alkenyl is selected from the group consisting of.

[0076] According to some embodiments, R 4 is C 5~25 alkyl. According to some embodiments, R 4 is C 5~10 alkyl. According to some embodiments, R 4 is C 10~18 alkyl. According to some embodiments, R 4 is C 18~25 alkyl. According to some embodiments, R 4 is C 5~25 alkenyl. According to some embodiments, R 4 is C 5~10 alkenyl. According to some embodiments, R 4 is C 10~18 alkenyl. According to some embodiments, R 4 is C 18~25 alkenyl. According to some embodiments, R 4 is C<00​​It is alkyl. According to several embodiments, R 4 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 4 C 5~15 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 4 C 5~15 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 4 C 5~15 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 4 C 5~15 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 4 C 5~15 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 4 C 5~15 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 That is the case.

[0077] According to several embodiments, R 5 C 1~4 Alkyl, C 0~10 Alkylene-OH, and C 0~10 Selected from the group consisting of alkylene-halogens. According to some embodiments, R 5 C 1~4 It is alkyl. According to several embodiments, R 5 C 0~10 It is an alkylene-OH group, according to several embodiments, 5 C 0~10 It is an alkylene halogen.

[0078] According to several embodiments, R 6 C 5~25 Alkyl, C 5~25 Selected from the group consisting of alkenyls. According to some embodiments, R 6 C 5~25 It is alkyl. According to several embodiments, R 6 C 5~25 It is an alkenyl. According to some embodiments, Y a OY b , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), pyrrolidinyl, piperidinylpiperazinyl, NH2, SH, NMe2, NMe3 + , and NH-Y b Selected from the group consisting of Y. According to some embodiments, a OY b Y a is a halogen. According to some embodiments, the halogen is selected from the group consisting of fluorine, chlorine, and bromine. According to some embodiments, the halogen is selected from the group consisting of fluorine and chlorine. According to some embodiments, the halogen is chlorine. According to some embodiments, Y a PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Selected from the group consisting of alkyl. According to some embodiments, Y a It is PO3H2. According to some embodiments, Y a is PO3(C 1~4 It is alkyl)2. According to some embodiments, Y a PO3H(C 1~4 It is alkyl. According to some embodiments, Y a SH is SH. According to some embodiments, Y a is NH2. According to several embodiments, Y a is NH(CH3). According to several embodiments, Y a This is N(CH3)2. According to some embodiments, Y ais pyrrolidine. According to several embodiments, Y a is piperidine. According to several embodiments, Y a is piperazine. According to some embodiments, Y a NH-Y b That is the case.

[0079] According to several embodiments, Y b H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl-Y c CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. According to some embodiments, Y b H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl-Y c CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. According to some embodiments, Y b C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl compounds.

[0080] According to several embodiments, Y b C 1~4It is alkyl. According to some embodiments, Y b C 1~4 It is an alkylene-OH group, according to some embodiments, Y b It is PO3H2. According to some embodiments, Y b is PO3(C 1~4 It is alkyl)2. According to some embodiments, Y b PO3H(C 1~4 It is alkyl. According to some embodiments, Y b CO-C 1~4 It is alkyl. According to some embodiments, Y b is a CO-aryl compound. According to some embodiments, the aryl compound is a phenyl compound that is optionally substituted with at least one alkyl, haloalkyl, or halogen compound. According to some embodiments, Y b It is SO3H. According to some embodiments, Y b SO3-(C 1~4 It is alkyl. According to some embodiments, Y b It is SO3-aryl. According to some embodiments, Y b C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH

[0081] According to several embodiments, Y c The group is selected from H, NH2, NH(CH3), N(CH3)2, pyrrolidinylpiperidinyl, and piperazinyl, and each pyrrolidinylpiperidinyl and piperazinyl is optionally C 1~4 Substituting with alkyl. Each possibility represents a distinct embodiment of the present invention.

[0082] According to several embodiments, Y a or Y c In either of these, pyrrolidinylpiperidinyl and piperazinyl are bonded via their respective nitrogen atoms. Each possibility represents a distinct embodiment of the present invention.

[0083] According to several embodiments, Y d OY e , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, SH, pyrrolidinyl, piperidinylpiperazinyl, NMe2, NMe3 + , and NH-Y e Selected from the group consisting of Y. According to some embodiments, d OY e Y d is a halogen. According to some embodiments, Y d PO3H2, PO3(C 1~4 It is alkyl)2. According to some embodiments, Y d PO3H(C 1~4 It is alkyl. According to some embodiments, Y d is NH2. According to several embodiments, Y d SH is SH. According to some embodiments, Y d is pyrrolidinyl. According to several embodiments, Y d is piperidinil. According to some embodiments, Y d is piperazinil. According to some embodiments, Y d It is NMe2. According to several embodiments, Y d NMe3 + Y d NH-Y e That is the case.

[0084] According to several embodiments, Y e H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl-Y f CO-aryl, SO3H, SO3-(C 1~4Selected from the group consisting of alkyl and SO3-aryl. According to some embodiments, Y e H is H. According to some embodiments, Y e C 1~4 It is alkyl. According to some embodiments, Y e C 1~4 It is an alkylene-OH group, according to some embodiments, Y e It is PO3H2. According to some embodiments, Y e is PO3(C 1~4 It is alkyl)2. According to some embodiments, Y e PO3H(C 1~4 It is alkyl. According to some embodiments, Y e CO-C 1~4 Alkyl-Y f Y e This is a CO-aryl. According to several embodiments, Y e It is SO3H. According to some embodiments, Y e SO3-(C 1~4 It is alkyl. According to some embodiments, Y e It is SO3-aryl.

[0085] According to several embodiments, Y f The group is selected from H, NH2, NH(CH3), N(CH3)2, pyrrolidinylpiperidinyl, and piperazinyl, and each pyrrolidinylpiperidinyl and piperazinyl is optionally C 1~4 Substituting with alkyl. Each possibility represents a distinct embodiment of the present invention.

[0086] According to several embodiments, R 1~4 Any one of the alkenyl groups (for example, C 5~25 Alkenyl is dienyl (for example, C 5~25 It is a dienyl. According to some embodiments, R 1~4 Any one of the alkenyl groups (for example, C 5~25 Alkenyls are monoenyls (for example, C 5~25It is mono-enyl.

[0087] According to several embodiments, R 2 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Selected from the group consisting of alkylene-CO2H; and R 4 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of R. According to several embodiments, 2 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Selected from the group consisting of alkylene-CO2H and LN(R3)-R4; and R 4 C 8~25 Alkyl, C 8~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0088] One of the features of the lipids of the present invention is that each nitrogen atom in chemical formula I contains at least one lipid moiety. According to several embodiments, R 1 and R 2 It has a total of at least 9 carbon atoms. According to some embodiments, R 3 and R 4 It has a total of at least 9 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 9 carbon atoms, and R 3 and R 4 It has a total of at least 9 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 10 carbon atoms. According to some embodiments, R 3 and R 4 It has a total of at least 10 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 10 carbon atoms, and R 3 and R 4 It has a total of at least 10 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 11 carbon atoms. According to some embodiments, R 3 and R 4It has a total of at least 11 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 11 carbon atoms, and R 3 and R 4 It has a total of at least 11 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 12 carbon atoms. According to some embodiments, R 3 and R 4 It has a total of at least 12 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 12 carbon atoms, and R 3 and R 4 It has a total of at least 12 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 13 carbon atoms. According to some embodiments, R 3 and R 4 It has a total of at least 13 carbon atoms. According to some embodiments, R 1 and R 2 It has a total of at least 13 carbon atoms, and R 3 and R 4 It has a total of 13 carbon atoms.

[0089] According to several embodiments, L a and L b Each of these is C 0~4 Alkylene or C 4~20 It is alkylene, L a and L b At least one of them is C 3~15 It is an alkylene. a and L b Each of these is C 0~20 It is alkylene, L a and L b At least one of them is C 3~15It is an alkylene. a and L b Each of these is C 0~20 It is an alkylene. a and L b At least one of them is C 3~15 It is an alkylene. a and L b Each of these is C 0~20 It is alkylene, L a and L b At least one of them is C 3~15 It is an alkylene. a and L b Each of these is C 0~15 It is an alkylene. a and L b At least one of them is C 5~15 It is an alkylene. a and L b Each of these is C 0~15 It is alkylene, L a and L b At least one of them is C 5~15 It is alkylene.

[0090] According to several embodiments, L a and L b Each of these is C 3~20 It is an alkylene. a and L b Each of these is C 3~15 It is alkylene.

[0091] According to several embodiments, L a and L b It has a total of at least 5 carbon atoms. According to some embodiments, L a and L b It has a total of at least 6 carbon atoms. According to some embodiments, L a and L bIt has a total of at least 7 carbon atoms. According to some embodiments, L a and L b It has a total of at least 8 carbon atoms. According to some embodiments, L a and L b It has a total of at least 9 carbon atoms. According to some embodiments, L a and L b It has a total of at least 10 carbon atoms. According to some embodiments, L a and L b It has a total of at least 11 carbon atoms. According to some embodiments, L a and L b It has a total of at least 12 carbon atoms.

[0092] According to several embodiments, R 1 C 8~18 Alkyl, C 8~18 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Alkyl, C 1~3 Alkylene-OH, C 1~3 Alkylene-O-CH2CH2-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 2~12 Alkylene-CO2H, C 5~10 Alkylene-CO2-C 5~10 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl and LN(R3)-R4; R 3 H, C 8~18 Alkyl and C 8~18 Alkenil, C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; and R 4 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkenyls.

[0093] According to several embodiments, X a -O2C-, -O-, -CO2-L c -O2C-, -O2C-L c -CO2-, -L c Selected from the group consisting of -O2C-, -CO2-NH-, and -CO-NH-; L a C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L b C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L c C 1~6 Alkylene-OC 1~6 Alkylene-, C 1~6 Alkylene-SSC 1~6 Alkylene and C 1~4 Selected from the group consisting of alkylenes; R 1 C 0~10 Alkilen-Y a , C 1~4 Alkyl, and C 5~25 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Selected from the group consisting of alkylene-CO2H; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 0~6 Alkilen-Y d , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; R 5 C 1~4 Alkyl, C 0~10 Alkylene-OH, and C 0~10 Selected from the group consisting of alkylenes and halogens; R 6 C 5~25 Alkyl, and C 5~25 Selected from a group consisting of alkenils; Y a OY bSelected from the group consisting of halogens, PO3H2, NH2, and NMe2; Y b H, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH and CO-C 1~4 Alkyl-Y c Selected from the group consisting of; Y c It is N(CH3)2; Y d OY e Selected from the group consisting of halogens and NH2; Y e H, and CO-C 1~4 Alkyl-Y f Selected from the group consisting of; and Y f It is selected from the group consisting of N(CH3)2 and piperazinyl, and it is optionally C 1~4 It is substituted with an alkyl group.

[0094] According to several embodiments, X a These are -O2C- and -CO2-L c Selected from the group consisting of -O2C-; L a C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L b C 4~20 Alkylene and C 0~4 Selected from the group consisting of alkylenes; L c C 1~4 It is alkylene; R 1 C 0~10 Alkilen-Y a and C 5~25 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenyl and C 2~15Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 5~25 Alkyl and C 0~6 Alkilen-Y d Selected from the group consisting of; R 4 C 5~25 Alkyl, C 5~25 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; R 5 C 0~10 It is alkylene-OH; R 6 C 5~25 It is an alkenil; Y a OY b and; Y b H is; Y d OY e and; and Y e H is H.

[0095] Chemical formula (I′) According to several embodiments, R 2 CH2CH2-R 22 Represented by; R 3 CH2CH2-R 23 Represented by; and R 4 CH2CH2-R 24 Represented by; Therefore, lipids are further represented by the structure of chemical formula (I'). According to some embodiments, R 1 is OH or CH2CH2-R 21 and; R 2 It contains at least 6 carbon atoms, CH2CH2-R 22 Represented by; R 3 CH2CH2-R 23 and; R 4 It contains at least 6 carbon atoms, CH2CH2-R 24 Represented by; R 1 , R 2 , R 3 , and R 4 None of them are H; Therefore, lipids are further represented by the structure of chemical formula (I').

[0096] The structure of chemical formula (I′) is shown below: [ka]

[0097] As can be understood by those skilled in the art, chemical formula (I') is a secondary structure of chemical formula (I) as presented herein. Thus, L and R as presented with respect to chemical formula (I) 1 The embodiments relating to can similarly be used to describe the chemical formula (I'). Also, R 1 One of the options is, as mentioned above, CH2CH2-R 21 Therefore, as can be understood by those skilled in the art, R includes a terminal ethylene group. 1 Each of the options shown above is CH2CH2-R 21 and R 21 Each of these sets may be converted to R. 1 C is an optional choice above. 5~25 Described as alkyl-, this embodiment is C 3~22 Alkyl(R) 1 R is described as (when the first two carbon atoms are each CH2) 21 It is acceptable to convert it to R. 1 C is an optional choice above. 0~10 Alkilen-Y a - is described as, and this embodiment is C 0~8 Alkilen-Y a (R 1R is described as (when the first two carbon atoms are each CH2) 21 It may be converted to R. Similarly, 2 CH2CH2-R 22 Represented by; R 3 CH2CH2-R 23 Represented by; and R 4 CH2CH2-R 24 This is expressed by . Therefore, a similar transformation is R 2~4 Considering the above embodiments regarding R 22~24 It may be done to explain this.

[0098] According to several embodiments, R 1 is OH or CH2CH2-R 21 According to several embodiments, R 1 is OH. According to some embodiments, R 1 CH2CH2-R 21 According to several embodiments, R 2 It contains at least 6 carbon atoms. According to some embodiments, R 2 It contains at least 7, 8, 9, 10, 11, or 12 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 22 It contains at least four carbon atoms. According to some embodiments, R 22 It contains at least 5, 6, 7, 8, 9, or 10 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 4 It contains at least 6 carbon atoms. According to some embodiments, R 4 It contains at least 7, 8, 9, 10, 11, or 12 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 24 It contains at least four carbon atoms. According to some embodiments, R 24 It contains at least 5, 6, 7, 8, 9, or 10 carbon atoms. According to some embodiments, R 1 , R 2 , R 3 , and R4 None of them are H.

[0099] According to several embodiments, R 21 C 0~8 Alkilen-Y a , C 2~4 Alkenirene-Y a , C 1~2 Alkyl, C 3~25 Alkyl, C 5~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, and C 3~13 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R 21 C 0~8 Alkilen-Y a According to several embodiments, R 21 C 2~4 Alkenirene-Y a According to several embodiments, R 21 C 1~2 It is alkyl. According to several embodiments, R 21 C 3~25 It is alkyl. According to several embodiments, R 21 C 5~23 It is an alkenyl. According to several embodiments, R 21 C 3~23 It is an alkynyl. According to several embodiments, R 21 C 3~13Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 21 C 3~13 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 21 C 3~13 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 21 C 3~13 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 21 C 3~13 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 21 C 3~13 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 21 C 3~13 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 21 C 3~13 Alkenylene-O2C-C 5~15 It is Alkenil.

[0100] According to several embodiments, R 22 C 4~23 Alkyl, C 4~23 Alkenil, C 4~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C3~13 Alkenylene-O2C-C 5~15 Alkenil, C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 0~13 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 Alkyl)2, and C 3~13 Selected from the group consisting of alkylene-CO2H. According to several embodiments, R 22 C 4~23 It is alkyl. According to several embodiments, R 22 C 4~23 It is an alkenyl. According to several embodiments, R 22 C 4~23 It is an alkynyl. According to several embodiments, R 22 C 3~13 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 22 C 3~13 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 22 C 3~13 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 22 C 3~13 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 22 C 3~13 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 22 C 3~13Alkenylene-CO2-C 5~15 Alkenyl. According to several embodiments, R 22 C 3~13 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 22 C 3~13 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 22 C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 22 C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 It is alkyl. According to several embodiments, R 22 C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 It is alkenyl)2, according to some embodiments, R 22 C 0~13 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl. According to several embodiments, R 22 C 0~13 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 22 C 3~13 It is alkylene-CO2H.

[0101] R 23 H, C 3~23 Alkyl, C 3~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C 3~13 Alkenylene-O2C-C 5~15 Alkenil, C 0~4 Alkilen-Y d , C 0~4 Alkenirene-Y d , and C 1~2 Selected from the group consisting of alkyl groups. According to several embodiments, R 23 H is H. According to some embodiments, R 23 C 3~23 It is alkyl. According to several embodiments, R 23 C 3~23 It is an alkenyl. According to several embodiments, R 23 C 3~23 It is an alkynyl. According to several embodiments, R 23 C 3~13 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 23 C 3~13 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 23 C 3~13 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 23 C 3~13 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 23 C 3~13 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 23 C 3~13 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 23 C 3~13Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 23 C 3~13 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 23 C 0~4 Alkilen-Y d According to several embodiments, R 23 C 0~4 Alkenirene-Y d According to several embodiments, R 23 C 1~2 It is alkyl. d This is a group, for example, related to chemical formula (I), as described in various embodiments of the present invention.

[0102] According to several embodiments, R 24 C 3~23 Alkyl, C 3~23 Alkenil, C 3~23 Alkinyl, C 3~13 Alkylene-CO2-C 5~15 Alkyl, C 3~13 Alkylene-CO2-C 5~15 Alkenil, C 3~13 Alkylene-O2C-C 5~15 Alkyl, C 3~13 Alkylene-O2C-C 5~15 Alkenil, C 3~13 Alkenylene-CO2-C 5~15 Alkyl, C 3~13 Alkenylene-CO2-C 5~15 Alkenil, C 3~13 Alkenylene-O2C-C 5~15 Alkyl, C 3~13 Alkenylene-O2C-C 5~15 Alkenyl and C 3~13 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0103] According to several embodiments. According to several embodiments, R 24C 3~23 It is alkyl. According to several embodiments, R 24 C 3~23 It is an alkenyl. According to several embodiments, R 24 C 3~23 It is an alkynyl. According to several embodiments, R 24 C 3~13 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 24 C 3~13 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 24 C 3~13 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 24 C 3~13 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 24 C 3~13 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 24 C 3~13 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 24 C 3~13 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 24 C 3~13 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 24 C 3~13 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 That is the case.

[0104] Chemical formula (I′′) According to several embodiments, R 22 CH2CH2-R 32 It is represented by R. According to several embodiments, 24 CH2CH2-R34 It is represented by R. According to several embodiments, 22 CH2CH2-R 32 It is represented by R 24 CH2CH2-R 34 Lipids are represented by the structure of chemical formula (I′′). According to some embodiments, R 2 CH2(CH2)3-R 32 It is represented by R. According to several embodiments, 4 CH2(CH2)3-R 34 It is represented by R. According to several embodiments, 2 CH2(CH2)3-R 32 Represented by R 4 CH2(CH2)3-R 34 Lipids are represented by the structure of chemical formula (I′′). Furthermore, according to several embodiments, as described in detail above, R 1 is OH or CH2CH2-R 21 It is acceptable for it to be, and R 3 CH2CH2-R 23 It is acceptable for R to be so. 1 , R 21 , R 3 and R 23 Any reference to this may also apply to each substituent of the chemical formula (I′′).

[0105] The structure of chemical formula (I′′) is shown below: [ka]

[0106] As can be understood by those skilled in the art, chemical formula (I′′) is a secondary structure of chemical formulas (I) and (I′) presented herein. Thus, L and R as presented with respect to chemical formulas (I) and / or (I′) 1 The embodiments relating to can similarly be used to explain the chemical formula (I′′). Also, R 1One of the options is, as mentioned above, CH2CH2-R 21 Therefore, as can be understood by those skilled in the art, R containing terminal ethylene groups 1 Each of the options shown above is CH2CH2-R 21 and R 21 Each of these sets may be converted to R. 1 C is an optional choice above. 5~25 Described as alkyl-, this embodiment is C 3~22 Alkyl(R) 1 R is described as (when the first two carbon atoms are each CH2) 21 It is acceptable to convert it to R. 1 C is an optional choice above. 0~10 Alkilen-Y a - is described as, and this embodiment is C 0~8 Alkilen-Y a (R 1 R is described as (when the first two carbon atoms are each CH2) 21 It is acceptable to convert it to this.

[0107] Similarly, according to several embodiments, R 22 CH2CH2-R 32 Represented by and / or R 2 CH2(CH2)3-R 32 This is expressed by - and therefore a similar transformation is R 2 (For example, when relating to chemical formula (I)) and / or R 22 Considering the embodiments previously described for (for example, in relation to chemical formula (I')), 32 This may be done to explain R. 2 C is optional. 5~15 Alkylene-CO2-C 5~15 As described above as alkyl - this embodiment is (a) C 3~13 Alkylene-CO2-C 5~15 Alkyl(R) 2 R is described as (when the first two carbon atoms are each CH2) 22 ; and / or (b) C1~11 Alkylene-CO2-C 5~15 Alkyl(R) 22 If the first two carbon atoms of each are CH2, that is, R 2 R is described as (when the first four carbon atoms are each CH2) 32 It may be converted to R. Similarly, according to several embodiments, 24 CH2CH2-R 34 Represented by and / or R 4 CH2(CH2)3-R 34 This is expressed by - and therefore a similar transformation is R 4 and / or R 24 Considering the embodiments previously described, R 34 This may be done to explain the R in chemical formula (I′′). 23 R is the R of chemical formula (I'). 23 It is as described below.

[0108] According to several embodiments, R 1 is OH or CH2CH2-R 21 According to several embodiments, R 1 is OH. According to some embodiments, R 1 CH2CH2-R 21 According to several embodiments, R 2 It contains at least 6 carbon atoms. According to some embodiments, R 2 It contains at least 7, 8, 9, 10, 11, or 12 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 32 It contains at least two carbon atoms. According to some embodiments, R 32 It contains at least 3, 4, 5, 6, 7, or 8 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 4 It contains at least 6 carbon atoms. According to some embodiments, R 4It contains at least 7, 8, 9, 10, 11, or 12 carbon atoms. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, R 34 It contains at least two carbon atoms. According to some embodiments, R 34 It contains at least 3, 4, 5, 6, 7, or 8 carbon atoms. According to some embodiments, R 1 , R 2 , R 3 , and R 4 None of them are H.

[0109] According to several embodiments, R 32 C 2~21 Alkyl, C 2~21 Alkenil, C 2~21 Alkinyl, C 1~11 Alkylene-CO2-C 5~15 Alkyl, C 1~11 Alkylene-CO2-C 5~15 Alkenil, C 1~11 Alkylene-O2C-C 5~15 Alkyl, C 1~11 Alkylene-O2C-C 5~15 Alkenil, C 2~11 Alkenylene-CO2-C 5~15 Alkyl, C 2~11 Alkenylene-CO2-C 5~15 Alkenil, C 2~11 Alkenylene-O2C-C 5~15 Alkyl, C 2~11 Alkenylene-O2C-C 5~15 Alkenil, C 0~11 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C0~11 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 1~11 Selected from the group consisting of alkylene-CO2H. According to several embodiments, R 32 C 2~21 It is alkyl. According to several embodiments, R 32 C 2~21 It is an alkenyl. According to several embodiments, R 32 C 2~21 It is an alkynyl. According to several embodiments, R 32 C 1~11 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 32 C 1~11 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 32 C 1~11 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 32 C 1~11 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 32 C 2~11 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 32 C 2~11 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 32 C 2~11 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 32 C 2~11 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 32 C 0~11 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 32 C0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 It is alkyl. According to several embodiments, R 32 C 0~13 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 It is alkenyl)2, according to some embodiments, R 32 C 0~11 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl. According to several embodiments, R 32 C 0~11 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 32 C 1~11 It is alkylene-CO2H.

[0110] R 34 C 1~21 Alkyl, C 2~21 Alkenil, C 2~21 Alkinyl, C 1~11 Alkylene-CO2-C 5~15 Alkyl, C 1~11 Alkylene-CO2-C 5~15 Alkenil, C 1~11 Alkylene-O2C-C 5~15 Alkyl, C 1~11 Alkylene-O2C-C 5~15 Alkenil, C 2~11 Alkenylene-CO2-C 5~15 Alkyl, C 2~11 Alkenylene-CO2-C 5~15 Alkenil, C 2~11 Alkenylene-O2C-C 5~15 Alkyl, C 2~11 Alkenylene-O2C-C 5~15 Alkenyl and C 1~11 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of According to several embodiments, R 34 C 1~21 It is alkyl. According to several embodiments, R 34 C 2~21 It is an alkenyl. According to several embodiments, R 34 C 2~21 It is an alkynyl. According to several embodiments, R 34 C 1~11 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 34 C 1~11 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 34 C 1~11 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 34 C 1~11 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 34 C 2~11 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 34 C 2~11 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 34 C 2~11 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 34 C 2~11 Alkenylene-O2C-C 5~15 Alkenyl and C 1~11 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 That is the case.

[0111] Chemical formula (I′′′) According to several embodiments, R 32 CH2(CH2)3-R 42 It is represented by R. According to several embodiments, 34CH2(CH2)3-R 44 It is represented by R. According to several embodiments, 32 CH2(CH2)3-R 42 It is represented by R 34 CH2(CH2)3-R 44 It is represented by, and therefore lipids are further represented by the structure of chemical formula (I′′′). According to some embodiments, R 2 CH2(CH2)7-R 42 It is represented by R according to several embodiments. 4 CH2(CH2)7-R 44 It is represented by R. According to several embodiments, 2 is CH2(CH2)7-R 42 It is represented by R 4 is CH2(CH2)7-R 44 Lipids are represented by the structure of chemical formula (I′′′). Furthermore, according to several embodiments, as will be described in detail above for chemical formulas (I′) and (I′′), R 1 is OH or CH2CH2-R 21 It is acceptable for it to be, and R 3 CH2CH2-R 23 It is acceptable for R to be so. 1 , R 21 , R 3 and R 23 Any reference to this may also apply to each substituent in the chemical formula (I′′′).

[0112] The structure of chemical formula (I′′′) is shown below: [ka]

[0113] As can be understood by those skilled in the art, chemical formula (I′′′) is a secondary structure of chemical formulas (I), (I′) and (I′′) presented herein. Thus, L and R as presented with respect to chemical formulas (I), (I′) and / or (I′′) 1The embodiments relating to can similarly be used to explain the chemical formula (I′′′). Also, R 1 One of the options is, as mentioned above, CH2CH2-R 21 And this too can be explained as described above.

[0114] Similarly, according to several embodiments, R 32 CH2(CH2)3-R 42 Represented by and / or R 2 CH2(CH2)7-R 32 This is expressed by - and therefore a similar transformation is R 2 (For example, when relating to chemical formula (I)) and / or R 32 Considering the embodiments previously described for (for example, in the case of chemical formula (I′′)), 42 This may be done to explain R. 2 C is optional. 5~15 Alkylene-CO2-C 5~15 As described above as alkyl - this embodiment is (a) C 3~13 Alkylene-CO2-C 5~15 Alkyl(R) 2 R is described as (when the first two carbon atoms are each CH2) 22 (b)C 1~11 Alkylene-CO2-C 5~15 Alkyl(R) 22 If the first two carbon atoms of each are CH2, that is, R 2 (When the first four carbon atoms are each CH2) and R 32 ; and (c)C 0~7 Alkylene-CO2-C 5~15 Alkyl(R) 22 At least C4 alkylene-CO2-C 5~15 If it is an alkyl group and the first four carbon atoms are each CH2, that is, R 2 Also, at least C4 alkylene-CO2-C 5~15 R is described as being alkyl, where the first eight carbon atoms are each CH2. 42It may be converted to R. Similarly, according to several embodiments, 34 CH2(CH2)3-R 44 Represented by and / or R 4 CH2(CH2)8-R 44 - is expressed by, and therefore a similar transformation is R 4 and / or R 34 Considering the embodiments previously described, R 44 This may be done to explain the R in the chemical formula (I′′′). 23 R is the R of the chemical formula (I′′) 23 It is as described below.

[0115] According to several embodiments, R 42 H, C 1~17 Alkyl, C 2~17 Alkenil, C 2~17 Alkinyl, C 0~7 Alkylene-CO2-C 5~15 Alkyl, C 0~7 Alkylene-CO2-C 5~15 Alkenil, C 0~7 Alkylene-O2C-C 5~15 Alkyl, C 0~7 Alkylene-O2C-C 5~15 Alkenil, C 2~7 Alkenylene-CO2-C 5~15 Alkyl, C 2~7 Alkenylene-CO2-C 5~15 Alkenil, C 2~7 Alkenylene-O2C-C 5~15 Alkyl, C 2~7 Alkenylene-O2C-C 5~15 Alkenil, C 0~11 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 0~7 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl, C 0~7 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 0~7Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 0~7 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 0~7 Selected from the group consisting of alkylene-CO2H. According to several embodiments, R 42 H is H. According to some embodiments, R 42 C 1~17 It is alkyl. According to several embodiments, R 42 C 2~17 It is an alkenyl. According to several embodiments, R 42 C 2~17 It is an alkynyl. According to several embodiments, R 42 C 0~7 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 42 C 0~7 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 42 C 0~7 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 42 C 0~7 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 42 C 2~7 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 42 C 2~7 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 42 C 2~7 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 42 C 2~7 Alkenylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 42 C 0~11Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 42 C 0~7 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 It is alkyl. According to several embodiments, R 42 C 0~7 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 It is alkenyl)2, according to some embodiments, R 42 C 0~7 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl. According to several embodiments, R 42 C 0~7 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2. According to some embodiments, R 42 C 0~7 It is alkylene-CO2H.

[0116] According to several embodiments, R 44 H, C 1~17 Alkyl, C 2~17 Alkenil, C 2~17 Alkinyl, C 0~7 Alkylene-CO2-C 5~15 Alkyl, C 0~7 Alkylene-CO2-C 5~15 Alkenil, C 0~7 Alkylene-O2C-C 5~15 Alkyl, C 0~7 Alkylene-O2C-C 5~15 Alkenil, C 2~7 Alkenylene-CO2-C 5~15 Alkyl, C 2~7 Alkenylene-CO2-C 5~15 Alkenil, C 2~7 Alkenylene-O2C-C 5~15 Alkyl, C 2~7 Alkenylene-O2C-C 5~15 Alkenyl and C0~7 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of R. According to several embodiments, 44 H is H. According to some embodiments, R 44 C 1~17 It is alkyl. According to several embodiments, R 44 C 2~17 It is an alkenyl. According to several embodiments, R 44 C 2~17 It is an alkynyl. According to several embodiments, R 44 C 0~7 Alkylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 44 C 0~7 Alkylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 44 C 0~7 Alkylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 44 C 0~7 Alkylene-O2C-C 5~15 It is an alkenyl. According to several embodiments, R 44 C 2~7 Alkenylene-CO2-C 5~15 It is alkyl. According to several embodiments, R 44 C 2~7 Alkenylene-CO2-C 5~15 It is an alkenyl. According to several embodiments, R 44 C 2~7 Alkenylene-O2C-C 5~15 It is alkyl. According to several embodiments, R 44 C 2~7 Alkenylene-O2C-C 5~15 Alkenyl and C 0~7 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 That is the case.

[0117] Chemical formula (Ia~c) L is L according to several embodiments. 1 -X 1 -L 2 , L 4 -X 2 -L 3 and L 7 -X 3 -L 8 The group is selected from the following. Therefore, according to some embodiments, the structure of chemical formula (I) is represented by the structure of chemical formula (Ia), the structure of chemical formula (Ib), or the structure of chemical formula (Ic): [ka] [ka] [ka]

[0118] L 1 , X 1 , L 2 , L 4 , X 2 , L 3 , L 7 , X 3 , and L 8 Each of these will be explained in this specification.

[0119] According to some embodiments, L is L 1 -X 1 -L 2 (i.e., chemical formula (Ia)); Here X 1 -O2C-, -CO2-L 3 -O2C-, -O2C-L 3 -CO2-, -CO2-L 3 -CO2-, L 3 -CO2- and L 3 Selected from the group consisting of -O2C-; L 1 and L 2Each of them is C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 3 C 1~6 Alkylene-(OC 1~6 Alkilen) n -, C 2~6 Alkenylene-(OC 1~6 Alkilen) m -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of n and m is either 0, 1, 2, 3, 4, or 5; R 1 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl and C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and LN(R) 3 )-R 4 Selected from the group consisting of; Or R 2 C 5~25Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Alkylene-O2C-C 5~15 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Each Y 1 OY 2 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, NMe2, and NH-Y 2 Selected from the group consisting of; and Y 2 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl; or L is L 4 -X 2 -L 5 (That is, chemical formula (Ib)); here X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 Selected from the group consisting of -O2C- and -CO-NH-; L 4 C 0~4 It is alkylene; L 5 C 2~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, C1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of j and k is either 0, 1, 2, 3, 4, or 5; R 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of; or R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Selected from the group consisting of alkyl groups; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15Selected from a group consisting of alkenils; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 Selected from the group consisting of; Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl; or Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4Alkyl), CO-C 1~4 Alkyl, CO-aryl, CO-C 1~4 Alkyl-N(CH3)2,SO3H,SO3-(C 1~4 Alkyl), NMe2, CO-C 1~4 Selected from the group consisting of alkyl-NM2 and SO3-aryl; or L is L 7 -X 3 -L 8 (That is, chemical formula (Ia)); here X 3 -O2C-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-; L 7 C 0~4 It is alkylene; L 8 C 0~4 Alkylene or C 4~20 It is alkylene; L 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of h and i is either 0, 1, 2, 3, 4, or 5; R 1 , R 2 and R 3 Each of them independently, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; and R 4 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; or R 1 C 5~25 Alkyl, C 5~25 Alkenyl and C 0~10 Alkylene-O-CO-C 1~4 Selected from the group consisting of alkyl-N(CH3)2; R 2 and R 4 Each of them independently, C 5~25Alkyl and C 5~25 Selected from a group consisting of alkenils; and R 3 H, C 5~25 Alkyl, and C 5~25 Selected from the group consisting of alkenyls. Chemical formula (Ia)

[0120] According to some embodiments, L is L 1 -X 1 -L 2 Therefore, according to some embodiments, the structure of chemical formula (I) is: [ka] It is represented by the structure of [this structure].

[0121] According to several embodiments, L a L 1 or L 2 According to several embodiments, L a L 1 According to several embodiments, L a L 2 According to several embodiments, L b L 1 or L 2 According to several embodiments, L b L 1 According to several embodiments, L b L 2 According to several embodiments, X a X 1 Therefore, L a , L b and X a The above detailed definitions regarding L are, where appropriate, 1 , L 2 and X 1 It is understood that the same can apply to this as well.

[0122] According to several embodiments, X 1 -O2C-, -CO2-L3 -O2C-, -O2C-L 3 -CO2-, -CO2-L 3 -CO2-, L 3 -CO2- and L 3 Selected from the group consisting of -O2C-. Each possibility represents a distinct embodiment.

[0123] According to several embodiments, L 1 and L 2 Each of them is C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes. Each possibility represents a distinct embodiment.

[0124] According to several embodiments, L 3 C 2~6 Alkenylene-(OC 1~6 Alkilen) m -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes. Each possibility represents a distinct embodiment. According to some embodiments, n and m in chemical formula (Ia) are 0, 1, 2, 3, 4, or 5. Each possibility represents a distinct embodiment.

[0125] According to several embodiments, R in chemical formula (Ia) 1 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment.

[0126] According to several embodiments, R in chemical formula (Ia) 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl and C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and LN(R 3 )-R 4 A selection is made from the group consisting of the following. Each possibility represents a distinct embodiment. According to some embodiments, R in chemical formula (Ia) 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 5~15 Alkylene-O2C-C 5~15 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2). Each possibility represents a distinct embodiment.

[0127] According to several embodiments, R in chemical formula (Ia) 3 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment.

[0128] According to several embodiments, R in chemical formula (Ia) 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. Each possibility represents a distinct embodiment. According to some embodiments, R in chemical formula (Ia) 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of

[0129] According to several embodiments, each Y 1 OY 2 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 2 Selected from the group consisting of. Each possibility represents a distinct embodiment. According to several embodiments, each Y 1 is, -Y 2 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, NMe2, and NH-Y 2 A selection is made from the group consisting of the following. Each possibility represents a distinct embodiment.

[0130] According to several embodiments, Y 2 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. Each possibility represents a distinct embodiment. According to some embodiments, Y 2 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4Selected from the group consisting of alkyl and SO3-aryl compounds.

[0131] Y a and Y b The above detailed definitions regarding Y are, where appropriate, 1 and Y 2 It is understood that the same can apply to this as well.

[0132] According to several embodiments, X 1 These are -O2C- and -CO2-L 3 Selected from the group consisting of -O2C-; L 1 and L 2 Each of them is C 5~15 It is alkylene; L 3 C 1~4 Alkilen- is; R 1 C 0~4 Alkilen-Y 1 and; R 2 C 9~20 Alkyl and C 9~20 Selected from a group consisting of alkenils; R 3 C 1~4 Alkilen-Y 1 and; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 Selected from the group consisting of; and each Y 1 It is OH.

[0133] According to several embodiments, X 1 -O2C-, -CO2-L 3 -O2C-, -O2C-L 3 -CO2-, -CO2-L 3 -CO2-, L 3 -CO2- and L3 Selected from the group consisting of -O2C-; L 1 and L 2 Each of them is C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 3 C 1~6 Alkylene-(OC 1~6 Alkilen) n -, C 2~6 Alkenylene-(OC 1~6 Alkilen) m -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of n and m is either 0, 1, 2, 3, 4, or 5; R 1 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl and C 5~15 Alkenylene-O2C-C 5~15 Alkenyl and LN(R 3 )-R4 Selected from the group consisting of; R 3 C 0~6 Alkilen-Y 1 , C 2~6 Alkenirene-Y 1 , and C 1~4 Selected from the group consisting of alkyl groups; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 1 OY 2 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and -NH-Y 2 Selected from the group consisting of; and Y 2 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl compounds.

[0134] According to several embodiments, R 1 C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 5~10 Alkylene-CO2-C 5~10 Alkenyl and LN(R 3 )-R 4 Selected from the group consisting of; R 3 C 1~3 Alkylene-OH,OH,C 1~3 Alkylene-halogen, C 1~3 Alkylene-PO3H2, methyl, ethyl, propyl, and C 1~3 Selected from the group consisting of alkylene-NH2; and R 4 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkenyls.

[0135] According to some embodiments, L is L 1 -X 1 -L 2 C 6~15 Alkylene-O2C-C 6~15 Alkilen, C 4~15 Alkylene-CO2-C 1~3 Alkylene-(OC 1~3 Alkilen) n -O2C-C 4~15 Alkylene and C 4~15 Alkylene-CO2-C 1~4 Alkylene-SSC 1~4 Alkylene-O2C-C 4~15 Selected from the group consisting of alkylenes; And n is 0, 1, or 2. According to several embodiments, R 1 CH2CH2PO3H2, CH2CH2Cl, CH2CH2OH, CH3, OH, and C 1~3 Selected from the group consisting of alkyl groups.

[0136] According to several embodiments, R 2 C 8~16 Alkyl, C 8~20 Alkenyl and LN(R 3 )-R 4 Selected from the group consisting of R. According to several embodiments, 3 CH2CH2PO3H2, CH2CH2Cl, CH2CH2OH, CH3, OH, and C 1~3 Selected from the group consisting of alkyl groups. According to several embodiments, R 4 C 8~16 Alkyl, C 8~20 Alkenyl and C 8~12 Alkylene-CO2-C 8~12 Selected from the group consisting of alkenyls. According to some embodiments, R 2 R 4 It is the same as R 1 R 3 It is the same as R 2 R 4 It is the same as R 1 R 3 It is the same as this.

[0137] The term "same" in the paragraph above should be understood to mean that the two R substituents identified have the same chemical definition. For example, the compound DSL1-1 shown below has the same R 2 and R 4 It has R1 and R 3 It has 2-hydroxyethyl and -(CH2)2-OH compounds, respectively.

[0138] According to several embodiments, the lipid of chemical formula (Ia) is DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1- 18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1 -28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL 1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DS L1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, D Selected from the group consisting of SL1-58, DSL1-59, DSL1-60, DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). Each possibility represents a distinct embodiment of the present invention.According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-3 4. Selected from the group consisting of DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL1-58, DSL1-59, DSL1-60 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). According to several embodiments, the lipids are selected from the group consisting of DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8. According to several embodiments, the lipids are selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, and DSL3c-1. The chemical structure of each compound is shown below (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).

[0139] Chemical formula (Ib) According to some embodiments, L is L 4 -X 2 -L 5 Therefore, according to some embodiments, the structure of chemical formula (I) is: [ka] It is represented by the structure of [this structure].

[0140] According to several embodiments, L a L 4 or L 5 According to several embodiments, L a L 4 According to several embodiments, L a L 5 According to several embodiments, L b L 4 or L 5 According to several embodiments, L b L 4 According to several embodiments, L b L 5 According to several embodiments, X a X 2 Therefore, L a , L b and X a The above detailed definitions regarding L are, where appropriate, 4 , L 5 and X 2 It is understood that the same can apply to this as well.

[0141] According to several embodiments, X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 The group is selected from -O2C- and -CO-NH-. Each possibility represents a distinct embodiment.

[0142] According to several embodiments, L 4 C 0~4 It is alkylene.

[0143] According to several embodiments, L 5 C 2~20 Alkylene and C4~20 Selected from the group consisting of alkenylenes. Each possibility represents a distinct embodiment.

[0144] According to several embodiments, L 6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes. Each possibility represents a distinct embodiment.

[0145] According to several embodiments, j and k in chemical formula (Ib) are 0, 1, 2, 3, 4, or 5, respectively. Each possibility represents a distinct embodiment.

[0146] According to several embodiments, R in chemical formula (Ib) 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment.

[0147] According to several embodiments, R in chemical formula (Ib) 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, and LN(R 3 )-R 4 A selection is made from the group consisting of the following. Each possibility represents a distinct embodiment. According to some embodiments, R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 Alkenil, C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl) 2, C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 Alkyl)2, and C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12Selected from the group consisting of alkyl groups. Each possibility represents a distinct embodiment of the present invention.

[0148] According to several embodiments, R in chemical formula (Ib) 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. Each possibility represents a distinct embodiment.

[0149] According to several embodiments, R in chemical formula (Ib) 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15Selected from the group consisting of alkenyls. Each possibility represents a distinct embodiment. According to several embodiments, Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 A selection is made from the group consisting of the following. Each possibility represents a distinct embodiment.

[0150] According to several embodiments, Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. Each possibility represents a distinct embodiment. According to some embodiments, Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH, C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 -OH,PO3H2,PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, CO-C 1~4 Alkyl-N(CH3)2,SO3H,SO3-(C 1~4 Alkyl), NMe2, CO-C 1~4 The group is selected from alkyl-NM2 and SO3-aryl compounds.

[0151] Y a and Y b The above detailed definitions regarding Y are, where appropriate, 3 and Y 4 It is understood that the same can apply to this as well.

[0152] According to several embodiments, X 2 It is -O2C-; L 4 C 0~4 Alkylene or C 4~20 It is alkylene; L 5 C 4~20 It is alkylene; R 1 C 0~10 Alkilen-Y 3 and; R 2 C 5~25 Alkyl, C 5~25 Alkenyl and C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 1~12 Selected from the group consisting of alkyl(2); R 3 C 5~25 It is alkyl; R 4 C 5~25 It is alkyl; Y 3 OY b and; and Y 4 H is H.

[0153] According to some embodiments, L is L 4 -X 2 -L 5 and; X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 Selected from the group consisting of -O2C- and -CO-NH-; L 4 C 0~4 It is alkylene; L 5 C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of j and k is either 0, 1, 2, 3, 4, or 5; R 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of; R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 Selected from the group consisting of; Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C)1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl. According to some embodiments, L is -O2C-C 6~12 Alkilen, C 1~3 Alkylene-CO2-C 1~3 Alkylene-SSC 1~3 Alkylene-O2C-C 4~10 Alkilen, C 1~3 Alkylene-CO2-C 6~12 Alkilen, C 1~3 Alkylene-OC 1~3 Alkylene-O2C-C 6~12 Alkylene and C 1~3 Alkylene-NHCO-C 6~12 Selected from the group consisting of alkylenes.

[0154] According to several embodiments, X 2 -O2C-, -CO2-L 6 -O2C-, -O2C-L 6 -CO2-, -CO2-L 6 -CO2-, L 6 -CO2-, L 6 Selected from the group consisting of -O2C- and -CO-NH-; L 4 C 0~4 It is alkylene; L 5 C 4~20 Alkylene and C 4~20 Selected from the group consisting of alkenylenes; L 6 C 1~6 Alkylene-(OC 1~6 Alkilen) j -, C 2~6 Alkenylene-(OC 1~6 Alkilen) k -, and C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC1~6 Selected from the group consisting of alkylenes; Each of j and k is either 0, 1, 2, 3, 4, or 5; R 1 C 0~10 Alkilen-Y 3 , C 2~6 Alkenirene-Y 3 , and C 1~4 Selected from the group consisting of alkyl groups; R 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, C 5~15 Alkenylene-O2C-C 5~15 Alkenil, C 5~15 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of

[0155] According to several embodiments, R 3 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; R 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; Y 3 OY 4 , halogen, PO3H2, PO3(C 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), NH2, and NH-Y 4 Selected from the group consisting of; and Y 4 H, C 1~4 Alkyl, C 1~4 Alkylene-OH,PO3H2,PO3(C) 1~4 Alkyl)2,PO3H(C 1~4 Alkyl), CO-C 1~4 Alkyl, CO-aryl, SO3H, SO3-(C 1~4 Selected from the group consisting of alkyl and SO3-aryl compounds.

[0156] According to several embodiments, R 1 C 8~18 Alkyl, C 8~18 Alkenil; C 1~3 Alkylene-OH, C 1~3 Alkylene-O-CH2CH2-OH, C 1~3 Alkylene-Cl, C 1~3 Alkylene-NH2, OH, and C 1~3 Selected from the group consisting of alkylene-PO3H2; R 2 C 8~18 Alkyl, C 8~18 Alkenil, C 2~12 Alkylene-CO2H, LN(R) 3 )-R 4 , and C 5~10 Alkylene-CO2-C 5~10 Selected from a group consisting of alkenils; R 3 H, C 8~18 Alkyl and C 8~18 Selected from a group consisting of alkenils; and R 4 C 8~18 Alkyl, C 8~18 Selected from the group consisting of alkenyls.

[0157] According to some embodiments, L is L 4 -X 2 -L 5 And, -O2C-C 6~12 Alkilen, C 1~3 Alkylene-CO2-C 6~12 Alkilen, C 1~3 Alkylene-CO2-C 1~3 Alkylene-SSC 1~3 Alkylene-O2C-C 4~10 Alkilen, C 1~3 Alkylene-OC 1~3 Alkylene-O2C-C 6~12 Alkylene and C 1~3 Alkylene-NHCO-C 6~12 Selected from the group consisting of alkylenes.

[0158] According to several embodiments, R in chemical formula (Ib) 1 R is selected from the group consisting of CH2CH2OH, CH2CH2OCH2CH2OH, CH2CH2Cl, OH, CH2CH2PO3H2, and CH2CH2NH2. According to some embodiments, R in chemical formula (Ib) 2 C 8~16 Alkyl, C 8~20 Alkenil, C 6~12 Alkylene-CO2-C 6~12 Alkenil, C 6~12 Alkylene-CO2H, and LN(R 3 )-R 4 Selected from the group consisting of

[0159] According to several embodiments, R in chemical formula (Ib) 3 H, C 6~16 Alkyl, and C 6~16 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ib) 4 C 6~16 Alkyl, C 6~16 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ib) 3 is R 4 It is the same as. The term “same” as used herein is defined with respect to parallel substituents of chemical formula (Ia).

[0160] According to several embodiments, the lipid of chemical formula (Ib) is DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2- 19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2-26, DSL2-27, DSL2-28, DSL2-29 , DSL2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DS L2-40, DSL2-41, DSL2-42, DSL2-43, DSL2-44, DSL2-45, DSL2-46, DSL2-47, DSL2-48, DSL2-49, DSL2 -50, DSL2-51, DSL2-52, DSL2-53, DSL2-54, DSL2-55, DSL2-56, DSL2-57, DSL2-58, DSL2-59, DSL2-60 The compounds are selected from the group consisting of DSL2-61, DSL2-62, DSL2-63, DSL2-64, DSL2-65, DSL2-66, DSL2-67, DSL2-68, DSL2-69, DSL2-70, DSL2-71, and DSL2-72 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). The chemical structures of each of the above compounds are shown below.

[0161] According to several exemplary embodiments, the lipids are selected from the group consisting of DSL2-1, DSL2-2, DSL2-49, and DSL2-50 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).

[0162] Chemical formula (Ic) According to some embodiments, L is L 7 -X 3 -L 8Therefore, according to some embodiments, the structure of chemical formula (I) is: [ka] It is represented by the structure of [this structure].

[0163] According to several embodiments, L a L 7 or L 8 According to several embodiments, L a L 7 According to several embodiments, L a L 8 According to several embodiments, L b L 7 or L 8 According to several embodiments, L b L 7 According to several embodiments, L b L 8 According to several embodiments, X a X 3 Therefore, L a , L b and X a The above detailed definitions regarding L are, where appropriate, 7 , L 8 and X 3 It is understood that the same can apply to this as well.

[0164] According to several embodiments, X 3 -O2C-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-. Each possibility represents a distinct embodiment. According to some embodiments, X 3 -O2C-, -CO2-NH-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9-CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-. Each possibility represents a distinct embodiment.

[0165] According to several embodiments, L 7 C 0~4 It is an alkylene. 8 C 0~4 It is an alkylene. 8 C 0~4 Alkylene or C 4~20 It is an alkylene. 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes. Each possibility represents a distinct embodiment. According to some embodiments, h and i are 0, 1, 2, 3, 4, or 5. Each possibility represents a distinct embodiment.

[0166] According to several embodiments, R 1 C 5~25 Alkyl, C 5~25 Alkenyl and C 0~10 Alkylene-O-CO-C 1~4 Selected from the group consisting of alkyl-N(CH3)2; R 2 and R 4 Each of them independently, C 5~25 Alkyl and C 5~25 Selected from a group consisting of alkenils; and R 3 H, C5~25 Alkyl, and C 5~25 Selected from the group consisting of alkenyls.

[0167] According to several embodiments, X 3 It is -O2C-; L 7 C 0~4 It is alkylene; L 8 C 0~4 It is alkylene; R 1 C 5~25 It is alkyl; and R 1 , R 2 , R 3 and R 4 Each of them is C 5~25 It is alkyl.

[0168] According to several embodiments, R in chemical formula (Ic) 1 , R 2 and R 3 Each of them independently, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic) 1 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic) 2 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic) 3 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0169] According to several embodiments, R in chemical formula (Ic) 4 H, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic) 4 C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0170] According to several embodiments, R in chemical formula (Ic) 1 , R 2 , R 3 and R 4 Each of them independently, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0171] According to some embodiments, L is L 7 -X 3 -L 8 and; X 3 -O2C-, -CO2-L 9 -O2C-, -O2C-L 9 -CO2-, -CO2-L 9 -CO2- and L 9 -CO2-, L 9 Selected from the group consisting of -O2C-; L7 C 0~4 It is alkylene; L 8 C 0~4 It is alkylene; L 9 C 0~4 Alkilen-aryl-C 0~4 Alkilen, C 1~4 Alkilen, C 1~6 Alkylene-(OC 1~6 Alkilen) h -, C 2~6 Alkenylene-(OC 1~6 Alkilen) i -, C 1~6 Alkilen-SC 1~6 Alkylene and C 1~6 Alkylene-SSC 1~6 Selected from the group consisting of alkylenes; Each of h and i is either 0, 1, 2, 3, 4, or 5; and R 1 , R 2 and R 3 Each of them independently, C 5~25 Alkyl, C 5~25 Alkenil, C 5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from a group consisting of alkenils; and R 4 H, C 5~25 Alkyl, C 5~25 Alkenil, C5~15 Alkylene-CO2-C 5~15 Alkyl, C 5~15 Alkylene-CO2-C 5~15 Alkenil, C 5~15 Alkylene-O2C-C 5~15 Alkyl, C 5~15 Alkylene-O2C-C 5~15 Alkenil, C 5~15 Alkenylene-CO2-C 5~15 Alkyl, C 5~15 Alkenylene-CO2-C 5~15 Alkenil, C 5~15 Alkenylene-O2C-C 5~15 Alkyl, and C 5~15 Alkenylene-O2C-C 5~15 Selected from the group consisting of alkenyls.

[0172] According to several embodiments, R in chemical formula (Ic) 1 C 8~18 Alkyl and C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl groups; R 2 C 8~18 Alkyl, C 8~18 Alkenyl and C 5~10 Alkylene-CO2-C 5~10 Selected from the group consisting of alkyl groups; R 3 H and C 8~18 Alkyl and C 8~18 Selected from a group consisting of alkenils; and R 4 C 8~18 It is alkyl.

[0173] According to some embodiments, L in chemical formula (Ic) is C 1~4 Alkylene-CO2-C 1~4 Alkilen, C 1~4 Alkylene-CO2-,O2C-C 1~3 Alkylene-C6H4-C 0~4 Alkylene-CO2, C 1~4Alkylene-OC 1~4 Alkylene-O2C-C 1~4 Alkilen, C 1~4 Alkylene-O2C-C 1~6 Alkylene-CO2-C 1~4 Alkylene, O2C-C 1~4 Alkylene-SSC 1~4 Alkylene-CO2 and O2C-C 1~6 It is selected from the group consisting of alkylene-CO2. "C6H4" is understood to refer to a phenylene group which is a divalent benzene. Depending on the bond position, the phenylene is selected from para-phenylene (where the two substituents are in a 1-4 position relationship), meta-phenylene (where the two substituents are in a 1-3 position relationship), and ortho-phenylene (where the two substituents are in a 1-2 position relationship). According to some embodiments, C6H4 is para-phenylene, which is shown below. [ka]

[0174] According to several embodiments, R in chemical formula (Ic) 1 C 8~15 Alkyl, C 8~20 Alkenyl and C 6~12 Alkylene-O2C-C 9~18 Selected from the group consisting of alkylenes. According to some embodiments, R in chemical formula (Ic) 2 C 8~15 Alkyl, C 8~20 Alkenyl and C 6~12 Alkylene-O2C-C 9~18 Selected from the group consisting of alkylenes. According to some embodiments, R in chemical formula (Ic) 3 C 8~15 Alkyl and C 8~20 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic) 4 H, C 8~15 Alkyl and C 8~20 Selected from the group consisting of alkenyls. According to some embodiments, R in chemical formula (Ic)4 C 8~15 Alkyl and C 8~20 Selected from the group consisting of alkenyls.

[0175] According to several embodiments, R 1 , R 2 , R 3 , and R 4 At least two of them represent the same substituent. According to some embodiments, R 1 , R 2 , R 3 , and R 4 At least three of these represent the same substituent. According to some embodiments, R 1 , R 2 , R 3 , and R 4 Each of these represents the same substituent. According to several embodiments, R 1 , R 2 , R 3 , and R 4 Two or fewer of these represent the same substituent. According to some embodiments, R 1 , R 2 , R 3 , and R 4 Three or fewer of these represent the same substituent. According to some embodiments, R 1 , R 2 , R 3 , and R 4 Each of these represents a different substituent.

[0176] The term “same” as used herein is defined with respect to parallel substituents of chemical formula (Ia). The term “different” refers to substituents that are not the same. For example, compounds DSL11, 12, and 14 are R 1 , R 2 , R 3 , and R 4 Each of these compounds represents a different substituent. Therefore, these compounds are "R 1 , R 2 , R 3 , and R 4 "Two or fewer / three or fewer substituents represent the same substituent" and "R 1 , R 2, R 3 , and R 4 This fits the definition that "each of them represents a different substituent."

[0177] According to several embodiments, the lipid of chemical formula (Ic) is selected from the group consisting of DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13, DSL4-14, and DSL4-15 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). The chemical structure of each compound is shown below.

[0178] According to several exemplary embodiments, the lipid is selected from the group consisting of DSL4-1 and DSL4-2 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). According to several exemplary embodiments, the lipid is DSL4-2.

[0179] Chemical formula (II) According to several embodiments, R 2 CH2(CH2)4-R 22 It is represented by R 3 CH2CH2-R 13 Represented by, and R 4 CH2(CH2)4-R 14 Lipids are represented by the structure of chemical formula (II). The structure of chemical formula (II) is shown below: [ka]

[0180] As can be understood by those skilled in the art, chemical formula (I') is a secondary structure of chemical formulas (I) and (I') presented herein. Thus, L and R as presented with respect to chemical formula (I) 1The embodiments relating to can similarly be used to explain chemical formula (II). Also, R 2 As mentioned above, CH2(CH2)4-R 12 Represented by and therefore understood by those skilled in the art, the above R includes four terminal CH2(CH2) groups. 2 The options are CH2(CH2)4-R 12 and / or R 12 Each of these sets may be converted to R. 2 C is an optional choice as described above. 5~25 As described above as an alkenyl - this embodiment is C 2~20 Alkyl(R) 2 R is described as such when the first five carbon atoms of each are CH2 and the alkenyls contain at least two carbon atoms. 12 It may be converted to R. Similarly, 3 CH2CH2-R 13 Represented by; R 4 CH2(CH2)4-R 14 This is expressed by . Therefore, a similar transformation is R 3~4 Considering the embodiments previously described, R 13~14 It may be done to explain this.

[0181] According to several embodiments, the lipids of the present invention are represented by the structure of chemical formula (II), Here R 1 and R 13 Each of them independently consists of OH and C. 1~3 alkyl-OH, C 4~14 Alkyl, and C 4~14 Selected from a group consisting of alkenils; R 12 C 1~13 Alkyl; C 2~15 Alkenil, C 1~6 Alkyl-CO2-C 0~3 Alkylene-N(C) 1~8 Alkyl)2 and C 1~6 Alkyl-CO2-C 0~3 Alkylene-NH-C 1~8Selected from the group consisting of alkyl groups; R 14 C 1~13 Alkyl, C 2~15 Alkenil, and [ka] Selected from the group consisting of; Each L is L a -X a -L b It is an alkylene ester linker represented by; X a -O2C-, -CO2-C 2~4 Alkylene-O2C-, O2C-C 2~4 Alkylene-O2C-,-CO2-C 2~4 Alkylene-CO2- and O2C-C 2~4 Selected from the group consisting of alkylene-CO2-; L a C 1~3 Alkilen, C 4~12 Alkilen, C 2~10 Selected from the group consisting of alkenylenes and their absence; and L b C 1~3 Alkilen, C 2~10 Alkenylene and C 4~12 Selected from the group consisting of alkylenes.

[0182] According to several embodiments, R 1 is OH, C 1~3 alkyl-OH, C 4~14 Alkyl and C 4~14 Selected from the group consisting of alkenyls. According to some embodiments, R 1 is OH, C 2~3 alkyl-OH, and C 8~14 Selected from the group consisting of alkyl groups. According to several embodiments, R 1 is OH. According to some embodiments, R 1 C 1~3 It is an alkyl-OH. According to some embodiments, R 1 C 2~3It is an alkyl-OH. According to some embodiments, R 1 C 4~14 It is alkyl. According to several embodiments, R 1 C 8~14 It is alkyl. According to several embodiments, R 1 C 4~14 It is Alkenil.

[0183] According to several embodiments, R 12 C 1~13 It is alkyl. According to several embodiments, R 12 C 2~15 It is an alkenyl. According to several embodiments, R 12 C 1~6 Alkyl-CO2-C 0~3 Alkylene-N(C) 1~8 It is alkyl)2. According to some embodiments, R 12 C 1~6 Alkyl-CO2-C 0~3 Alkylene-NH-C 1~8 It is alkyl. According to several embodiments, R 12 C 9~15 Alkenil, C 5~11 Alkyl, C 3~6 Alkyl-CO2-C 0~2 Alkylene-N(C) 2~8 Selected from the group consisting of alkyl)2. According to several embodiments, R 12 C 9~15 It is an alkenyl. According to several embodiments, R 12 C 5~11 It is alkyl. According to several embodiments, R 12 C 3~6 Alkyl-CO2-C 0~2 Alkylene-N(C) 2~8 It is alkyl(2).

[0184] According to several embodiments, R 13 is OH, C 1~3 alkyl-OH, C 4~14 Alkyl and C 4~14Selected from the group consisting of alkenyls. According to some embodiments, R 13 is OH. According to some embodiments, R 13 C 1~3 It is an alkyl-OH. According to some embodiments, R 13 C 4~14 It is alkyl. According to several embodiments, R 1 C 4~14 It is an alkenyl. According to several embodiments, R 13 These are OH, CH2-OH, and C 4~12 Selected from the group consisting of alkyl groups. According to several embodiments, R 13 It is CH2-OH. According to some embodiments, R 13 C 4~12 It is alkyl.

[0185] According to several embodiments, R 14 C 1~13 Alkyl; C 2~15 Alkenil and [ka] Selected from the group consisting of

[0186] According to several embodiments, C 1~13 Alkyl. According to several embodiments, R 14 C 2~15 It is an alkenyl. According to several embodiments, R 14 teeth: [ka] That is the case.

[0187] According to several embodiments, R 14 C 9~15 Alkenil, C 1~9 Alkyl and [ka] Selected from the group consisting of

[0188] According to several embodiments, R 14 C 9~15 It is an alkenyl. According to several embodiments, R 14 C 1~9 It is alkyl.

[0189] According to several embodiments, each L (i.e., L and R of chemical formula (II)) 14 The L of (or both) is L a -X a -L b It is an alkylene ester linker represented by L. a , X a , and L b The descriptions of various secondary structures (e.g., chemical formula (I)) are as explained above.

[0190] According to several embodiments, X a -O2C-, -CO2-C 2~4 Alkylene-O2C-, O2C-C 2~4 Alkylene-O2C-,-CO2-C 2~4 Alkylene-CO2- and O2C-C 2~4 Selected from the group consisting of alkylene-CO2-. According to some embodiments, X a is -O2C-. According to some embodiments, X a is -CO2-C 2~4 It is alkylene-O2C-. According to several embodiments, X a O2C-C 2~4 It is alkylene-O2C-. According to several embodiments, X a is -CO2-C 2~4 It is alkylene-CO2-. According to several embodiments, X a O2C-C 2~4 It is alkylene-CO2-. According to several embodiments, X a -O2C- and -CO2-C 2~4 Selected from the group consisting of alkylene-O2C-

[0191] According to several embodiments, L a C 1~3 Alkilen, C 4~12 Alkilen, C 2~10 Selected from the group consisting of alkenylenes and their absence. According to some embodiments, L a C 1~3 It is an alkylene. a C 4~12 It is an alkylene. a C 2~10 It is an alkenylene. a L is nonexistent. According to some embodiments, a C 2~3 Alkylene and C 6~11 Selected from the group consisting of alkylenes. According to several embodiments, L a C 2~3 It is an alkylene. a C 6~11 It is alkylene.

[0192] According to several embodiments, L b C 1~3 Alkilen, C 2~10 Alkenylene and C 4~12 Selected from the group consisting of alkylenes. According to several embodiments, L b C 1~3 It is an alkylene. b C 2~10 It is an alkenylene. b C 4~12 It is an alkylene. b C 1~3 Alkylene and C 4~12 Selected from the group consisting of alkylenes. According to several embodiments, L b C 1~3 It is an alkylene. b C 4~12 It is alkylene.

[0193] According to several embodiments, the lipid of chemical formula (II) is selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-13, DSL1-14, DSL1-15, DSL1-20, DSL1-58, DSL3c-1, DSL3c-4, DSL2-1, DSL2-2, DSL2-13, DSL2-14, DSL2-16, DSL2-29, DSL2-49, DSL2-50, DSL2-54, DSL2-63, DSL2-65, DSL4-1, DSL4-2, DSL2-5, and DSL2-7. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the lipid of chemical formula (II) is selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL3c-1, DSL2-1, DSL2-2, DSL2-49, DSL2-50, DSL4-1, and DSL4-2. According to several embodiments, the lipid of chemical formula (II) is selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL3c-1, DSL2-1, DSL2-2, DSL2-49, DSL2-50, DSL4-1, and DSL4-2. According to several embodiments, the lipid is selected from the group consisting of DSL1-3 and DSL2-50.

[0194] The chemical structures of each specific compound are described in detail in the "Exemplary Compounds" section and claims below.

[0195] Exemplary compounds Exemplary compounds according to the chemical formulas (I), (I′), (I′′), (I′′′), (Ia), (Ib), (Ic), and (II) of the present invention are shown below. It should be understood that, according to several embodiments, the present invention is not limited to any one or more of the exemplary compounds shown below.

[0196] According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DS L1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46 , DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL1-58, DSL1-59, DSL1-60, DSL3c-1, DSL3 c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7 and DSL3c-8, DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2-19, DSL2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2- 26, DSL2-27, DSL2-28, DSL2-29, DSL2-30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DSL2-40, DSL2-41, DS L2-42, DSL2-43, DSL2-44, DSL2-45, DSL2-46, DSL2-47, DSL2-48, DSL2-49, DSL2-50, DSL2-51, DSL2-52, DSL2-53, DSL2-54, DSL2-55, DSL2-56, DSL2-57,Selected from the group consisting of DSL2-58, DSL2-59, DSL2-60, DSL2-61, DSL2-62, DSL2-63, DSL2-64, DSL2-65, DSL2-66, DSL2-67, DSL2-68, DSL2-69, DSL2-70, DSL2-71, DSL2-72, DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13, DSL4-14, and DSL4-15 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). Each possibility represents a distinct embodiment of the present invention.

[0197] The following exemplary compounds are described as non-limiting examples of lipids of the present invention. The substituents of each lipid are identified below, sometimes in curly braces {}, for the purpose of distinguishing most specific embodiments.

[0198] Specifically, compound DSL1-1 is shown below. [ka]

[0199] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here, Y b is H; R 2 is C 5~25 alkenyl{C 18 diene chain}; R 3 is C 0~6 alkylene - Y d {C2 alkylene - Y d}; Here, Y d is O - Y e ; Here, Y e is H; and R 4 is C 5~25 alkenyl{C 18 diene chain}. It is understood that DSL1 - 1 may also be represented by other chemical formulas described herein (e.g., chemical formula (II)). Compound DSL1 - 2 is shown below.

Chemical formula

[0201] Compound DSL1-3 is shown below. [ka]

[0202] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a , in other words, Y a It is only; Here Y a OY b and; Here Y b H is; R 2C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain. Although it is understood that DSL1-3 may also be represented by other chemical formulas described herein (e.g., chemical formula (II)).

[0203] Compound DSL1-4 is shown below. [ka]

[0204] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkyl {C12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL1-4 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0205] Compound DSL1-5 is shown below. [ka]

[0206] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL1-5 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0207] Compound DSL1-6 is shown below. [ka]

[0208] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {That is, C2 alkylene-(O-C2 alkylene) f} and; Here f is 1; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10Alkilen-Y a {That is, C2 alkylene-Y a} and; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0209] Compound DSL1-7 is shown below. [ka]

[0210] It is represented by chemical formula (I), where L is L a -X a -L b X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a , in other words, Y a It is only; Here Y aOY b and; Here Y b H is; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 C 0~6 Alkilen-Y d {C0 Alkylene-Y} d , in other words, Y d It is only; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0211] Compound DSL1-8 is shown below. [ka]

[0212] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a , in other words, Y a It is only; Here Y a OY b and; Here Yb H is; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C0 Alkylene-Y} d , in other words, Y d It is only; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0213] Compound DSL1-9 is shown below. [ka]

[0214] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a , in other words, Y a It is only; Here Y a OY b and; Here Y b H is; R 2C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C0 Alkylene-Y} d , in other words, Y d It is only; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0215] Compound DSL1-10 is shown below. [ka]

[0216] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O2C-L c It is -CO2-; L c C 1~6 Alkylene-SSC 1~6 It is alkylene {C1alkylene-SS-C1alkylene}; L a C 4~20 It is alkylene {C8 alkylene}; L b C 4~20 It is alkylene {C8 alkylene}; R 1 It is OH, as detailed in DSL1-7; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3It is OH, as detailed in DSL1-7; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0217] Compound DSL1-11 is shown below. [ka]

[0218] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed for DSL1-5; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~10 Alkilen-Y d and; Here Y d It is NMe2; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0219] Compound DSL1-12 is shown below. [ka]

[0220] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {That is, C2 alkylene-Y a} and; Here Y a It is a halogen {chlorine}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {That is, C2 alkylene-Y d} and; Here Y d It is a halogen {chlorine}; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0221] Compound DSL1-13 is shown below. [ka]

[0222] It is represented by chemical formula (I), where L is L a -X a-L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a , in other words, Y a It is only; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain. It is understood that DSL1-13 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0223] Compound DSL1-14 is shown below. [ka]

[0224] It is represented by chemical formula (I), where L is L a -Xa -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-3; and R 4 C 5~25 Alkenyl {C 18 It is alkenil. It is understood that DSL1-14 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0225] Compound DSL1-15 is shown below. [ka]

[0226] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C0 Alkylene-Y} d , in other words, Y d It is only; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is alkenil. It is understood that DSL1-15 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0227] Compound DSL1-16 is shown below. [ka]

[0228] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is PO3H2; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0229] Compound DSL1-17 is shown below. [ka]

[0230] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is a halogen {chlorine}; R 2 C5~25 Alkenyl {C 18 It is a diene chain; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0231] Compound DSL1-18 is shown below. [ka]

[0232] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is PO3H2; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0233] Compound DSL1-19 is shown below. [ka]

[0234] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is a halogen {chlorine}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d OY e and; Here Y e H is; and R 4 C 5~25Alkenyl {C 18 It is a diene chain.

[0235] Compound DSL1-20 is shown below. [ka]

[0236] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl as shown with respect to DSl1-1; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 It is hydroxyethyl as shown with respect to DSl1-1; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain. It is understood that DSL1-20 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0237] Compound DSL1-21 is shown below. [ka]

[0238] It is represented by chemical formula (I), where L is L a -X a -L band; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~6 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b H is; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 0~10 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d It is a halogen {chlorine}; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0239] Compound DSL1-22 is shown below. [ka]

[0240] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; Lb C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in relation to DSL1-18; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 It is hydroxyethyl, as detailed in relation to DSL1-18; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0241] Compound DSL1-23 is shown below. [ka]

[0242] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in DSL1-7; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0243] Compound DSL1-24 is shown below. [ka]

[0244] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 As detailed in DSL1-7, it is OH; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 0~10 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d It is PO3H2; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0245] Compound DSL1-25 is shown below. [ka]

[0246] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in DSL1-7; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkenyl {C 18 It is alkenil.

[0247] Compound DSL1-26 is shown below. [ka]

[0248] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R4 C 5~25 Alkenyl {C 18 It is alkenil.

[0249] Compound DSL1-27 is shown below. [ka]

[0250] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0251] Compound DSL1-28 is shown below. [ka]

[0252] It is represented by chemical formula (I), where L is L a -Xa -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0253] Compound DSL1-29 is shown below. [ka]

[0254] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0255] Compound DSL1-30 is shown below. [ka]

[0256] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0257] Compound DSL1-31 is shown below. [ka]

[0258] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in DSL1-7; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 It is CH2CH2-PO3H2, as detailed in relation to DSL1-24; and R 4 C 5~25 Alkenyl {C 18 It is alkenil.

[0259] Compound DSL1-32 is shown below. [ka]

[0260] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1It is chloroethyl, as detailed in relation to DSL1-12; R 3 It is CH2CH2-PO3H2, as detailed in relation to DSL1-24; R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0261] Compound DSL1-33 is shown below. [ka]

[0262] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25It is an alkenyl {C9 alkenyl}.

[0263] Compound DSL1-34 is shown below. [ka]

[0264] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 It is CH2CH2-PO3H2, as detailed in relation to DSL1-24; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0265] Compound DSL1-35 is shown below. [ka]

[0266] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; La C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl{methyl}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0267] Compound DSL1-36 is shown below. [ka]

[0268] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; L c C 1~6 Alkylene-SSC 1~6 It is alkylene {C2alkylene-SS-C2alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C10 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkyl {C 11 It is alkyl.

[0269] Compound DSL1-37 is shown below. [ka]

[0270] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; L c C 1~6 Alkylene-SSC 1~6 It is alkylene {C2alkylene-SS-C2alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkyl {C 10 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkyl {C 11 It is alkyl.

[0271] Compound DSL1-38 is shown below. [ka]

[0272] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is alkylene {C8 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 It is an alkenyl {C9 alkenyl}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}.

[0273] Compound DSL1-39 is shown below. [ka]

[0274] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl{methyl}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 1~4 It is alkyl{methyl}; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0275] Compound DSL1-40 is shown below. [ka]

[0276] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0277] Compound DSL1-41 is shown below. [ka]

[0278] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl{propyl}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0279] Compound DSL1-42 is shown below. [ka]

[0280] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a and; Here Y a It is NH2; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0281] Compound DSL1-43 is shown below. [ka]

[0282] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~15 Alkylene-CO2-C5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 C 0~10 Alkilen-Y d and; Here Y d It is NH2; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0283] Compound DSL1-44 is shown below. [ka]

[0284] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0285] Compound DSL1-45 is shown below. [ka]

[0286] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 11 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0287] Compound DSL1-46 is shown below. [ka]

[0288] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0289] Compound DSL1-47 is shown below. [ka]

[0290] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0291] Compound DSL1-48 is shown below. [ka]

[0292] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0293] Compound DSL1-49 is shown below. [ka]

[0294] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0295] Compound DSL1-50 is shown below. [ka]

[0296] It is represented by chemical formula (I), where L is L a -X a -L b X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0297] Compound DSL1-51 is shown below. [ka]

[0298] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is aminoethyl, as detailed in relation to DSL1-43; and R 4 C 5~25 Alkenyl {C 18 It is alkenil.

[0299] Compound DSL1-52 is shown below. [ka]

[0300] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d CO-C 1~4 Alkyl-Y f {CO-C2alkyl-Y f} and; Here Y f C 1~4 Alkyl-substituted piperazinyl {1-piperazinyl with methyl substitution at position 4}; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0301] Compound DSL1-53 is shown below. [ka]

[0302] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkenyl {C18 It is a diene chain; R 3 C 0~6 Alkilen-Y d {C2 alkylene-Y} d} and; Here Y d CO-C 1~4 Alkyl-Y f {CO-C3alkyl-Y f} and; Here Y f It is N(CH3)2; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0303] Compound DSL1-54 is shown below. [ka]

[0304] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 Alkylene {C 10 It is an alkylene; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkenyl {C 18It is a diene chain.

[0305] Compound DSL1-55 is shown below. [ka]

[0306] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is NMe2; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0307] Compound DSL1-56 is shown below. [ka]

[0308] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is dimethylaminoethyl, as detailed with respect to DSL1-55; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0309] Compound DSL1-57 is shown below. [ka]

[0310] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; Here L c C 1~4 It is an alkylene {C2 alkylene}; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is dimethylaminoethyl, as detailed with respect to DSL1-55; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 It is CH2CH2-PO3H2, as detailed in relation to DSL1-24; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0311] Compound DSL1-58 is shown below. [ka]

[0312] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~15 Alkylene-O2C-C 5~15 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-O2C-C1alkylene-N(C8alkyl)2}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R4 C 5~25 Alkenyl {C 18 It is a diene chain. It is understood that DSL1-58 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0313] Compound DSL1-59 is shown below. [ka]

[0314] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is dimethylaminoethyl, as detailed with respect to DSL1-55; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 Alkyl)2{C 10 It is alkylene-CO2-C0alkylene-N(C8 alkyl)2; R 3 It is chloroethyl, as detailed in relation to DSL1-12; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0315] Compound DSL1-60 is shown below. [ka]

[0316] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b C 1~4 It is alkylene-OH{C2alkylene-OH}; R 2 This is identical to the base described in detail with respect to DSL1-59; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; and R 4 C 5~25 Alkenyl {C 18 It is a diene chain.

[0317] Compound DSL3C-1 is shown below. [ka]

[0318] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20Alkylene {C 10 It is an alkylene; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 0~10 It is alkylene-OH{C2alkylene-OH}; and R 6 C 5~25 Alkenyl {C 18 It is a diene chain. It is understood that DSL3C-1 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0319] Compound DSL3C-2 is shown below. [ka]

[0320] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl(ethyl); R 2 C 5~25 It is an alkenyl {C9 alkenyl}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 1~4 It is alkyl(ethyl); and R 6 C 5~25 It is an alkenyl {C9 alkenyl}.

[0321] Compound DSL3C-3 is shown below. [ka]

[0322] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl{n-propyl}; R2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 1~4 It is alkyl{n-propyl}; and R 6 C 5~25 Alkenyl {C 18 It is a dienyl.

[0323] Compound DSL3C-4 is shown below. [ka]

[0324] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3It is hydroxyethyl, as detailed with respect to DSL1-1; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C 10 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 0~10 It is alkylene-OH{C2alkylene-OH}; and R 6 C 5~25 It is alkyl {C18 alkyl}. It is understood that DSL3C-4 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0325] Compound DSL3C-5 is shown below. [ka]

[0326] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl{n-propyl}; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 1~4It is alkyl{n-propyl}; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 1~4 It is alkyl{n-propyl}; and R 6 C 5~25 Alkenyl {C 18 It is a dienyl.

[0327] Compound DSL3C-6 is shown below. [ka]

[0328] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 It is an alkenyl {C9 alkenyl}; R 3 It is chloroethyl, as detailed in relation to DSL1-12; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6{C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 0~10 It is an alkylene halogen {chloroethyl}; and R 6 C 5~25 It is an alkenyl {C9 alkenyl}.

[0329] Compound DSL3C-7 is shown below. [ka]

[0330] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 It is an alkenyl {C9 alkenyl}; R 3 It is hydroxyethyl, as detailed with respect to DSL1-1; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 0~10It is alkylene-OH{C2alkylene-OH}; and R 6 C 5~25 It is an alkenyl {C9 alkenyl}.

[0331] Compound DSL3C-8 is shown below. [ka]

[0332] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 It is an alkenyl {C9 alkenyl}; R 3 It is CH2CH2-PO3H2, as detailed in relation to DSL1-24; R 4 C 5~15 Alkylene-CO2-C 5~15 Alkylene-N(R) 5 )R 6 {C9 Alkylene-CO2-C 10 Alkylene-N(R) 5 )R 6} and; R 5 C 0~10 It is alkylene-OH{C2alkylene-OH}; and R 6 C 5~25 It is an alkenyl {C9 alkenyl}.

[0333] Compound DSL2-1 is shown below. [ka]

[0334] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is a diene chain; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL2-1 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0335] Compound DSL2-2 is shown below. [ka]

[0336] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL2-2 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0337] Compound DSL2-3 is shown below. [ka]

[0338] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO2-L c -O2C-; L c C 1~6 Alkylene-SSC 1~6 It is alkylene {C2alkylene-SS-C2alkylene}; L a C 0~4 It is alkylene {C1 alkylene}; L b C 4~20 It is alkylene {C7 alkylene}; R1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0339] Compound DSL2-4 is shown below. [ka]

[0340] It is represented by chemical formula (I), where L is L a -X a -L b X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b C 1~4 It is alkylene-OH{C2alkylene-OH}; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0341] Compound DSL2-5 is shown below. [ka]

[0342] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0343] Compound DSL2-6 is shown below. [ka]

[0344] It is represented by chemical formula (I), where L is L a -X a -L b and; X aIt is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0345] Compound DSL2-7 is shown below. [ka]

[0346] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0347] Compound DSL2-8 is shown below. [ka]

[0348] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-121; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0349] Compound DSL2-9 is shown below. [ka]

[0350] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Here Y b C 1~4 It is alkylene-OH{C2alkylene-OH}; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0351] Compound DSL2-10 is shown below. [ka]

[0352] It is represented by chemical formula (I), where L is L a -X a -L b and; Xa L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 10 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0353] Compound DSL2-11 is shown below. [ka]

[0354] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 This is an alkenyl {C9 alkenyl}.

[0355] Compound DSL2-12 is shown below. [ka]

[0356] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0357] Compound DSL2-13 is shown below. [ka]

[0358] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl. Although it is to be understood, DSL2-13 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0359] Compound DSL2-14 is shown below. [ka]

[0360] It is represented by chemical formula (I), where L is L a -X a -L band; X a It is -O2C-; L a C 4~20 Alkylene {C 10 It is an alkylene; L b C 0~4 It is alkylene {C1 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl. It is understood that DSL2-14 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0361] Compound DSL2-15 is shown below. [ka]

[0362] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0363] Compound DSL2-16 is shown below. [ka]

[0364] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl. It is understood that DSL2-16 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0365] Compound DSL2-17 is shown below. [ka]

[0366] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0367] Compound DSL2-18 is shown below. [ka]

[0368] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0369] Compound DSL2-19 is shown below. [ka]

[0370] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0371] Compound DSL2-20 is shown below. [ka]

[0372] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0373] Compound DSL2-21 is shown below. [ka]

[0374] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0375] Compound DSL2-22 is shown below. [ka]

[0376] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0377] Compound DSL2-23 is shown below. [ka]

[0378] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0379] Compound DSL2-24 is shown below. [ka]

[0380] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0381] Compound DSL2-25 is shown below. [ka]

[0382] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0383] Compound DSL2-26 is shown below. [ka]

[0384] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~15 It is alkylene-CO2H{C9alkylene-CO2H}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0385] Compound DSL2-27 is shown below. [ka]

[0386] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl {C9 alkylene-CO2-C0 alkylene-NH-C 10 It is alkyl; R 3 H is; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0387] Compound DSL2-28 is shown below. [ka]

[0388] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0389] Compound DSL2-29 is shown below. [ka]

[0390] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule. It is understood that DSL2-29 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0391] Compound DSL2-30 is shown below. [ka]

[0392] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl {C9 alkylene-CO2-C0 alkylene-NH-C9 alkenyl}; R 3 H is; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0393] Compound DSL2-31 is shown below. [ka]

[0394] It is represented by chemical formula (I), where L is L a -X a -L b and; Xa It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 1~12 Alkyl {C9 alkylene-CO2-C0 alkylene-NH-C 10 It is alkyl; R 3 H is; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0395] Compound DSL2-32 is shown below. [ka]

[0396] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO2-C 0~8Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0397] Compound DSL2-33 is shown below. [ka]

[0398] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl {C9 alkylene-CO2-C0 alkylene-NH-C9 alkenyl}; R 3 H is; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0399] Compound DSL2-34 is shown below. [ka]

[0400] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-NH-C 5~25 It is an alkenyl {C9 alkylene-CO2-C0 alkylene-NH-C9 alkenyl}; R 3 H is; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0401] Compound DSL2-35 is shown below. [ka]

[0402] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~15 Alkylene-CO2-C 5~15 It is an alkenyl {C9 alkylene-CO2-C9 alkenyl}; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0403] Compound DSL2-36 is shown below. [ka]

[0404] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~15 It is alkylene-CO2H{C9alkylene-CO2H}; R 3 H is; and R4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0405] Compound DSL2-37 is shown below. [ka]

[0406] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0407] Compound DSL2-38 is shown below. [ka]

[0408] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0409] Compound DSL2-39 is shown below. [ka]

[0410] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0411] Compound DSL2-40 is shown below. [ka]

[0412] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0413] Compound DSL2-41 is shown below. [ka]

[0414] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0415] Compound DSL2-42 is shown below. [ka]

[0416] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0417] Compound DSL2-43 is shown below. [ka]

[0418] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0419] Compound DSL2-44 is shown below. [ka]

[0420] It is represented by chemical formula (I), where L is L a -X a -L b and; Xa It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0421] Compound DSL2-45 is shown below. [ka]

[0422] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 4~20 It is an alkylene {C9 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0423] Compound DSL2-46 is shown below. [ka]

[0424] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is aminoethyl, as detailed in relation to DSL1-42; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0425] Compound DSL2-47 is shown below. [ka]

[0426] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c-O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C0 Alkylene-Y} a That is, R 1 is Y a} and; Here Y a OY b and; Y b CO-C 1~4 Alkyl-Y c {CO-C3alkyl-Y c} and here Y c It is N(CH3)2; R 2 C 5~25 Alkyl {C 10 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0427] Compound DSL2-48 is shown below. [ka]

[0428] It is represented by chemical formula (I), where L is La -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a OY b and; Y b CO-C 1~4 Alkyl-Y c {CO-C3alkyl-Y c} and here Y c It is N(CH3)2; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0429] Compound DSL2-49 is shown below. [ka]

[0430] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is alkyl {C6 alkyl}. It is understood that DSL2-49 may also be represented by other chemical formulas as described herein (e.g., chemical formula (II)).

[0431] Compound DSL2-50 is shown below. [ka]

[0432] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C)1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule. It is understood that DSL2-50 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0433] Compound DSL2-51 is shown below. [ka]

[0434] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a {C4 Alkylene-Y} a} and; Here Y a OY b and; Here Y b H is; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0435] Compound DSL2-52 is shown below. [ka]

[0436] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a and; Here Y a OY b and; Here Y b C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 It is -OH{C2 alkylene-(O-C2 alkylene)1-OH}; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0437] Compound DSL2-53 is shown below. [ka]

[0438] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is alkylene {C6 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C6alkylene-CO2-C0alkylene-N(C9alkyl)2}; R 3 C 5~25 It is alkyl {C9 alkyl}; and R 4 C 5~25 It is an alkyl (C9 alkyl) molecule.

[0439] Compound DSL2-54 is shown below. [ka]

[0440] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C0 alkylene-N(C6 alkyl)(C8 alkyl)}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C8 alkyl) group. It is understood that DSL2-54 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0441] Compound DSL2-55 is shown below. [ka]

[0442] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C0~4 Alkylene-N(C) 5~25 It is alkenyl)2{C9alkylene-CO2-C0alkylene-N(C9alkenyl)2}; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0443] Compound DSL2-56 is shown below. [ka]

[0444] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a and; Here Y a It is NMe2; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0445] Compound DSL2-57 is shown below. [ka]

[0446] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0447] Compound DSL2-58 is shown below. [ka]

[0448] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0449] Compound DSL2-59 is shown below. [ka]

[0450] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~4 Alkylene-N(C) 5~25 Alkenyl)2{C2alkylene-CO2-C0alkylene-N(C 18It is dienyl)2; R 3 C 5~25 Alkenyl {C 18 It is dienyl; and R 4 C 5~25 Alkenyl {C 18 It is a dienyl.

[0451] Compound DSL2-60 is shown below. [ka]

[0452] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is alkylene {C4 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 Alkyl)2{C4alkylene-CO2-C0alkylene-N(C 12 Alkyl)2} is; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0453] Compound DSL2-61 is shown below. [ka]

[0454] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a and; Here Y a OY b and; Here Y b C 1~4 It is alkylene-OH{C2alkylene-OH}; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9alkylene-CO2-C0alkylene-N(C6alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0455] Compound DSL2-62 is shown below. [ka]

[0456] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f -{C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-CH2CH2OCH2CH2-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-CH2CH2OCH2CH2-N(C62 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C6 alkyl{C 12 It is alkyl.

[0457] Compound DSL2-63 is shown below. [ka]

[0458] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C4~20 It is an alkylene {C9 alkylene}; R 1 It is OH, as detailed in relation to DSL1-3; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule. It is understood that DSL2-63 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0459] Compound DSL2-64 is shown below. [ka]

[0460] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 1~4 It is alkyl(propyl); R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0461] Compound DSL2-65 is shown below. [ka]

[0462] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule. It is understood that DSL2-65 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0463] Compound DSL2-66 is shown below. [ka]

[0464] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0465] Compound DSL2-67 is shown below. [ka]

[0466] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R1 C 0~10 Alkilen-Y a {C2 alkylene-Y} a} and; Here Y a It is NMe2; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0467] Compound DSL2-68 is shown below. [ka]

[0468] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0469] Compound DSL2-69 is shown below. [ka]

[0470] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 C 0~10 Alkilen-Y a It is a {C2 alkylene}; Here Y a OY b and; Here Y b C 1~4 Alkylene-(OC 1~4 Alkilen) 1-3 It is -OH{C2 alkylene-(O-C2 alkylene)1-OH}; R 2 C 2~15 Alkylene-CO2-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO2-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0471] Compound DSL2-70 is shown below. [ka]

[0472] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is hydroxyethyl, as detailed with respect to DSL1-1; R 2 C 2~15 Alkylene-CO-NH-C 0~8 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO-NH-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0473] Compound DSL2-71 is shown below. [ka]

[0474] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is chloroethyl, as detailed in relation to DSL1-12; R 2 C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO-NH-C2 alkylene-N(C6 alkyl)2}; R 3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0475] Compound DSL2-72 is shown below. [ka]

[0476] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -CO-NH-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 4~20 It is an alkylene {C9 alkylene}; R 1 It is CH2CH2-PO3H2, as detailed in DSL1-16; R 2 C 2~15 Alkylene-CO-NH-C 0~4 Alkylene-N(C) 1~12 It is alkyl)2{C9 alkylene-CO-NH-C2 alkylene-N(C6 alkyl)2}; R3 C 5~25 It is alkyl {C6 alkyl}; and R 4 C 5~25 It is an alkyl (C6 alkyl) molecule.

[0477] Compound DSL4-1 is shown below. [ka]

[0478] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL4-1 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0479] Compound DSL4-2 is shown below. [ka]

[0480] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl. It is understood that DSL4-2 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0481] Compound DSL4-3 is shown below. [ka]

[0482] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O2C-L c It is -CO2-; L c C 0~4 Alkilen-aryl-C 0~4It is alkylene {C1alkylene-para-C6H4-C1alkylene}; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; R 1 C 5~25 Alkyl {C 10 It is alkyl; R 2 C 5~25 Alkyl {C 10 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0483] Compound DSL4-4 is shown below. [ka]

[0484] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 This is a C9 alkenyl.

[0485] Compound DSL4-5 is shown below. [ka]

[0486] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O2C-L c It is -CO2-; L c C 1~4 It is alkylene {C4 alkylene}; L a C 0~4 It is an alkylene {C2 alkylene}; L b C 0~4 It is an alkylene {C2 alkylene}; R 1 C 12 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkenyl {C 18 It is dienyl; and R 4 C5~25 Alkyl {C 12 It is alkyl. It is understood that DSL4-5 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0487] Compound DSL4-6 is shown below. [ka]

[0488] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6 Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 It is an alkyl {C8 alkenyl}; and R 4 It is a C8 alkyl{C9 alkenyl}.

[0489] Compound DSL4-7 is shown below. [ka]

[0490] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is an alkenil; R 3 C 5~25 Alkenyl {C 18 It is an alkenil; and R 4 C 5~25 Alkyl {C 11 It is alkyl. It is understood that DSL4-7 may also be represented by other chemical formulas listed herein (e.g., chemical formula (II)).

[0491] Compound DSL4-8 ​​is shown below. [ka]

[0492] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C0~4 It is an alkylene {C2 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 It is an alkenyl {C9 alkenyl}; and R 4 C 5~25 It is an alkenyl {C9 alkenyl}.

[0493] Compound DSL4-9 is shown below. [ka]

[0494] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O2C-L c It is -CO2-; L c C 1~6 Alkylene-SSC 1~6 It is alkylene {C1alkylene-SS-C1alkylene}; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; R 1 C 5~25 Alkyl {C 10 It is alkyl; R 2 C 5~25Alkyl {C 10 It is alkyl; R 3 C 5~25 Alkyl {C 10 It is alkyl; and R 4 C 5~25 Alkyl {C 10 It is alkyl.

[0495] Compound DSL4-10 is shown below. [ka]

[0496] It is represented by chemical formula (I), where L is L a -X a -L b and; X a is -O2C-L c It is -CO2-; L c C 1~4 It is alkylene {C4 alkylene}; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; R 1 C 5~25 Alkyl {C 12 It is alkyl; R 2 C 5~25 Alkyl {C 12 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0497] Compound DSL4-11 is shown below. [ka]

[0498] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -CO2-NH-; L a C 0~4 It is alkylene {C1 alkylene}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~25 Alkyl {C 10 It is alkyl; R 2 C 5~25 Alkyl {C 10 It is alkyl; R 3 H is; and R 4 C 5~25 Alkyl {C 20 It is alkyl.

[0499] Compound DSL4-12 is shown below. [ka]

[0500] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4It is alkylene {C1 alkylene}; R 1 C 5~15 Alkylene-CO2-C 5~15 Alkyl {C8 alkylene-CO2-C 15 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkenyl {C 18 It is alkenil. The variables are similar for DSL4-12 and DSL4-15, but the difference lies in the orientation of L, which is not limited by chemical formula (I) - in DSL4-12, L a R 1 and R 2 Adjacent to and L b R 3 and R 4 Adjacent to, on the other hand, in DSL4-15, L a R 3 and R 4 Adjacent to, L b R 1 and R 2 It is adjacent to.

[0501] Compound DSL4-13 is shown below. [ka]

[0502] It is represented by chemical formula (I), where L is L a -X a -L b and; X a L c -O2C-; Here L c C 1~6Alkylene-(OC 1~6 Alkilen) f {C2 alkylene-(O-C2 alkylene) f} and; Here, f is 1; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~15 Alkylene-CO2-C 5~15 Alkyl {C8 alkylene-CO2-C 15 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkenyl {C 18 It is alkenil.

[0503] Compound DSL4-14 is shown below. [ka]

[0504] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C5~15 Alkylene-CO2-C 5~15 Alkyl {C8 alkylene-CO2-C 15 It is alkyl; R 2 C 5~15 Alkylene-CO2-C 5~15 Alkyl {C8 alkylene-CO2-C 15 It is alkyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R 4 C 5~25 Alkyl {C 12 It is alkyl.

[0505] Compound DSL4-15 is shown below. [ka]

[0506] It is represented by chemical formula (I), where L is L a -X a -L b and; X a It is -O2C-; L a C 0~4 It is an alkylene {C0 alkylene, i.e., non-existent}; L b C 0~4 It is alkylene {C1 alkylene}; R 1 C 5~15 Alkylene-CO2-C 5~15 Alkyl {C8 alkylene-CO2-C 15 It is alkyl; R 2 C 5~25 Alkenyl {C 18 It is dienyl; R 3 C 5~25 Alkyl {C 12 It is alkyl; and R4 C 5~25 Alkenyl {C 18 It is alkenil. The variables are similar for DSL4-12 and DSL4-15, but the difference lies in the orientation of L, which is not limited by chemical formula (I) - in DSL4-12, L a R 1 and R 2 Adjacent to, L b R 3 and R 4 Adjacent to, on the other hand, in DSL4-15, L a R 3 and R 4 Adjacent to, L b R 1 and R 2 It is adjacent to.

[0507] Then, according to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL 1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, D SL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-34, DSL1-35, DSL1-36, DSL1-37, DSL1-38 , DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1- 48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL Selected from the group consisting of 1-58, DSL1-59, DSL1-60, DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).According to the embodiment, the lipids are DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL1-6, DSL1-7, DSL1-8, DSL1-9, DSL1-10, DSL1-11, DSL1-12, DSL1-13, DSL1-14, DSL1-15, DSL1-16, DSL1-17, DSL1-18, DSL1-19, DSL1-20, DSL1-21, DSL1-22, DSL1-23, DSL1-24, DSL1-25, DSL1-26, DSL1-27, DSL1-28, DSL1-29, DSL1-30, DSL1-31, DSL1-32, DSL1-33, DSL1-3 4. Selected from the group consisting of DSL1-35, DSL1-36, DSL1-37, DSL1-38, DSL1-39, DSL1-40, DSL1-41, DSL1-42, DSL1-43, DSL1-44, DSL1-45, DSL1-46, DSL1-47, DSL1-48, DSL1-49, DSL1-50, DSL1-51, DSL1-52, DSL1-53, DSL1-54, DSL1-55, DSL1-56, DSL1-57, DSL1-58, DSL1-59, DSL1-60 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). According to several embodiments, the lipids are selected from the group consisting of DSL3c-1, DSL3c-2, DSL3c-3, DSL3c-4, DSL3c-5, DSL3c-6, DSL3c-7, and DSL3c-8 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).According to the process embodiment, the lipids are DSL2-1, DSL2-2, DSL2-3, DSL2-4, DSL2-5, DSL2-6, DSL2-7, DSL2-8, DSL2-9, DSL2-10, DSL2-11, DSL2-12, DSL2-13, DSL2-14, DSL2-15, DSL2-16, DSL2-17, DSL2-18, DSL2-19, DSL 2-20, DSL2-21, DSL2-22, DSL2-23, DSL2-24, DSL2-25, DSL2-26, DSL2-27, DSL2-28, DSL2-29, DSL2- 30, DSL2-31, DSL2-32, DSL2-33, DSL2-34, DSL2-35, DSL2-36, DSL2-37, DSL2-38, DSL2-39, DSL2-40 , DSL2-41, DSL2-42, DSL2-43, DSL2-44, DSL2-45, DSL2-46, DSL2-47, DSL2-48, DSL2-49, DSL2-50, D SL2-51, DSL2-52, DSL2-53, DSL2-54, DSL2-55, DSL2-56, DSL2-57, DSL2-58, DSL2-59, DSL2-60, DSL Selected from the group consisting of 2-61, DSL2-62, DSL2-63, DSL2-64, DSL2-65, DSL2-66, DSL2-67, DSL2-68, DSL2-69, DSL2-70, DSL2-71, and DSL2-72 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). According to several embodiments, the lipids are selected from the group consisting of DSL4-1, DSL4-2, DSL4-3, DSL4-4, DSL4-5, DSL4-6, DSL4-7, DSL4-8, DSL4-9, DSL4-10, DSL4-11, DSL4-12, DSL4-13, DSL4-14, and DSL4-15 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).According to several exemplary embodiments, lipids are selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL3C-1, DSL2-1, DSL2-2, DSL4-1, and DSL4-2 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof). According to several exemplary embodiments, lipids are selected from the group consisting of DSL1-1, DSL1-2, DSL1-3, DSL1-4, DSL1-5, DSL3C-1, DSL2-1, DSL2-2, DSL2-49, DSL2-50, DSL4-1, and DSL4-2 (including salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, optical isomers, diastereomers, and mixtures thereof).

[0508] chemical definition As used herein, the term “cationic lipid” refers to a lipid species that has a net positive charge at a selected pH. The selected pH value includes, but is not limited to, the physiological pH of pH=7. It will be understood by those skilled in the art that the lipids of the present invention may be considered cationic lipids because they have two or more nitrogen atoms, these atoms are typically basic, and are protonable at a selected pH, and thus the compound may have a net positive charge. According to some embodiments, the lipids of the present invention are cationic lipids.

[0509] The "alkyl" group refers to any saturated aliphatic hydrocarbon, including linear and branched alkyl groups. Alkyl groups may be unsubstituted or substituted with one or more groups selected from halogens, hydroxyl, alkoxycarbonyl, amide, alkylamide, dialkylamide, nitro, amino, alkylamino, dialkylamino, carboxyl, thio, and thioalkyl groups. n~mThe term "alkyl" refers to an alkyl group having n to m carbon atoms. Formulatually, an alkyl group corresponds to an alkane having one CH bond substituted by the site of attachment of the alkyl group to the rest of the compound. Examples of alkyl moieties include chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, and sec-butyl; and include, but are not limited to, highly similar cognate groups such as 2-methyl-1-butyl, 3-pentyl, hexyl, and 1,2,2-trimethylpropyl. The term "alkylene," used alone or in combination with other terms, refers to a divalent alkyl linking group. Formulatually, an alkylene group corresponds to an alkane having two CH bonds substituted by the site of attachment of the alkylene group to the rest of the compound. n~m "Alkylene" refers to an alkylene group having n to m carbon atoms. Examples of alkylene groups include, but are not limited to, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-1,1-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, and 2-methylpropane-1,3-diyl. C0-alkylene should be understood as meaning the absence of a particular substituent. For example, substituent C 0~4 Alkilen-aryl-C 0~4 When referring to alkylenes, if both values ​​are 0, the substituent is a divalent aryl (e.g., phenylene, C6H4). Also, L is L a -X a -L b is; and L a and L b If we refer to each of them as a C0 alkylene, then L is X a In each section of this application, the range of alkyl chains is, for example, C 0~4 Alkyl, C 4~20 Alkyl, C 4~14 It is represented as alkyl, etc. It should be understood that such a range includes any sub-range within that range. For example, C 4~14 Alkyl is C 4~8 Alkyl, C 8~14 Alkyl, C 6~12It may include alkyl groups, C9 alkyl groups, etc., and / or may target them.

[0510] The “alkenyl” group refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond, and includes linear, branched, and cyclic alkenyl groups. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbuta-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl, and decenyl. The alkenyl group may be unsubstituted or may be substituted via available carbon atoms with one or more groups defined above in relation to alkyl groups. The alkenyl according to the present invention may contain two or more carbon-carbon double bonds. Therefore, dienes (e.g., compound DSL1-1, substituent R) 2 and R 4 See also) and trienes are within the definition of alkenyls. According to some embodiments, alkenyls are dienyles. n~m The term "alkenyl" refers to an alkyl group having n to m carbon atoms. The alkenyl group formally corresponds to an alkene having one CH bond substituted by the site of attachment of the alkenyl group to the rest of the compound. Examples of alkenyl moieties include, but are not limited to, chemical groups such as ethenyl, propenyl, isopropenyl, n-butenyl, and sec-butenyl. The term "alkenylene," used alone or in combination with other terms, refers to a divalent alkenyl linkage group. The alkenylene group formally corresponds to an alkane having two CH bonds substituted by the site of attachment of the alkenylene group to the rest of the compound. n~m "Alkenylene" refers to an alkenylene having n to m carbon atoms. In each section of this application, the range of the alkenyl chain is, for example, C 2~8 Alkenil, C 4~20 It is represented by alkenils, etc. Such ranges should be understood to include any sub-range. For example, C 4~14 Alkenil is C 4~8 Alkenil, C 8~14 Alkenil, C 6~12This may include alkenyls, C9 alkenyls, etc., and / or may target them.

[0511] One or more of the lipids of the present invention may exist as salts. The term "salt" includes, but is not limited to, carboxylate salts or salts having an amine nitrogen atom, encompassing both base addition salts and acid addition salts, and salts formed with organic and inorganic anions and cations as described later. Furthermore, this term includes salts resulting from standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Examples of such acids include hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, acetic acid, succinic acid, citric acid, lactic acid, maleic acid, fumaric acid, palmitic acid, cholic acid, pamoic acid, mucoic acid, D-glutamic acid, D-camphoric acid, glutaric acid, phthalic acid, tartaric acid, lauric acid, stearic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, sorbic acid, picric acid, benzoic acid, cinnamic acid, and others. Each possibility represents a distinct embodiment of the present invention.

[0512] The term “organic or inorganic cation” refers to the counterion for the anion of a salt. Counterions include, but are not limited to, alkali metals and alkaline earth metals (such as lithium, sodium, potassium, barium, aluminum, and calcium); ammonium and mono-, di-, and tri-alkylamines (such as trimethylamine and cyclohexylamine); and organic cations (such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, and dibenzylethylenediammonium). See, for example, Berge et al., J. Pharm. Sci. (1977), 66:1-19; this reference is incorporated herein by reference.

[0513] Particles, compositions and uses According to several embodiments, the present invention provides particles comprising lipids and membrane-stabilizing lipids according to the present invention. Accordingly, in several aspects, the present invention provides compositions comprising lipids according to any one of the chemical formulas (I), (I′), (I′′), (I′′′), (Ia), (Ib), (Ic), and (II), for example, any one of the compounds DSL1-1 to DSL1-60, DSL3c-1 to DSL3c-8, DSL2-1 to DSL2-72, or DSL4-1 to DSL4-15, and pharmaceutically acceptable additives.

[0514] According to several embodiments, compositions comprising a plurality of particles and pharmaceutically acceptable carriers, diluents, or additives as disclosed herein are provided. According to several embodiments, the composition is a liposome composition. According to several embodiments, the particles of the present invention are in the form of liposomes. In other embodiments, the composition further comprises one or more components selected from the group consisting of neutral lipids, charged lipids, steroids, and polymer-complexed lipids. Each possibility represents a distinct embodiment of the present invention.

[0515] According to several embodiments, the particles include a membrane-stabilizing lipid and a lipid membrane. According to several embodiments, the membrane-stabilizing lipid is selected from the group consisting of cholesterol, phospholipids, kephalins, sphingolipids, and glyceroglycolipids. According to several embodiments, the membrane-stabilizing lipid includes cholesterol.

[0516] According to several embodiments, the membrane-stabilizing lipids may be selected from, but are not limited to, the following: Cholesterol, phospholipids (e.g., phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerols, etc.), kephalins, sphingolipids (sphingomyelins and sphingoglycolipids), glyceroglycolipids, and combinations thereof. Each possibility represents a distinct embodiment of the present invention.

[0517] In some embodiments, the phosphatidylethanolamines may be selected from, but are not limited to, the following: 1,2-Dilauroyl-L-phosphatidylethanolamine (DLPE), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Difitanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), 1,3-Dipalmitoyl-sn-glycero-2-phosphoethanolamine (1,3-DPPE), 1-Palmitoyl-3-oleoyl-sn-glycero-2-phosphoethanolamine (1,3-POPE), Biotin-phosphatidylethanolamine, 1,2-Dimiristoyl-sn-glycero-3-phosphoethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or combinations thereof. In some embodiments, the phosphatidylethanolamines may be complexed with PEG-amine derivatives. Each possibility represents a distinct embodiment of the present invention.

[0518] In some embodiments, “neutral lipids” refers to any of numerous lipid species that exist in either an uncharged or neutral amphoteric form at physiological pH, and such lipids include, but are not limited to, the following: Phosphatidylcholines (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), etc.); phosphatidylethanolamines (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), etc.); sphingomyelins (SM), ceramides, steroids (sterols), and their derivatives. Neutral lipids may be synthetic or naturally derived.

[0519] According to several embodiments, the particles further comprise one or more additional components selected from the group consisting of PEG lipid complexes, neutral lipids, and charged lipids. According to several embodiments, the additional component comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). According to several embodiments, the additional component comprises 1,2-dimiristoyl-sn-glyceryl-methoxypolyethylene glycol (DMG-PEG).

[0520] According to several embodiments, the particles (their lipid phase) may further contain one or more PEG derivatives. In some embodiments, the PEG derivatives may be complexed with one or more additional molecules, such as lipids. In some embodiments, the PEG derivatives are selected from, but are not limited to, the following: PEG-DMG 3-N-(-methoxypoly(ethylene glycol)2000)carbamoyl-1,2-dimyristylglycerol, PEG-cDMA 3-N-(-methoxypoly(ethylene glycol)2000)carbamoyl-1,2-dimyristyloxypropylamine; PEG-cDSA 3-N-(-methoxypoly(ethylene glycol)2000)carbamoyl-1,2-distearyloxypropylamine, DSPE-PEG, PEG-maleimide, DSPE-PEG-maleimide, or combinations thereof. Each possibility represents a distinct embodiment of the present invention.

[0521] According to several embodiments, the particles comprise lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-dimiristoyl-sn-glyceryl-methoxypolyethylene glycol (DMG-PEG). According to several embodiments, the particles comprise the lipids of the present invention, membrane-stabilizing lipids, additional phospholipids, and PEG lipid complexes.

[0522] According to several embodiments, the ratios of the various lipids in the particles may differ. In some embodiments, the ratio is a molar ratio. In some embodiments, the ratio is a weight ratio. In some embodiments, each of the lipid groups may have a molar ratio / weight ratio of about 1% to 99%. According to several embodiments, the particles contain 10 to 70% mol% of the lipids according to the present invention, 20 to 80% mol% of membrane-stabilizing lipids, 5 to 50% of additional phospholipids, and 0.5 to 10% of PEG lipid complexes. According to several embodiments, the mol% of lipids is at least 10 mol% of the particles. According to several embodiments, the mol% of lipids is at least 15 mol% of the particles. According to several embodiments, the mol% of lipids is at least 20 mol% of the particles. According to several embodiments, the mol% of lipids is at least 25 mol% of the particles. According to several embodiments, the mol% of lipids is 50 mol% or less of the particles. According to several embodiments, the mol% of lipids is 45 mol% or less of the particles. According to some embodiments, the mol% of lipids is 40 mol% or less of the particles. According to some embodiments, the mol% of lipids is 35 mol% or less of the particles.

[0523] The expression "the mole percentage of lipids is at least x moles of the particle" is understood to mean that at least x percent of the particle's molecules are lipids. The same terminology reflects the other components of this particle. Similarly, the expression "the mole percentage of lipids is less than or equal to x moles of the particle" means that less than or equal to x percent of the particle's molecules are lipids. The unit "mol%" is also sometimes written as "mol:mol" or "%mol:mol".

[0524] According to some embodiments, the molar percentage of additional phospholipids is at least 5 mol% of the particles. According to some embodiments, the molar percentage of additional phospholipids is at least 10 mol% of the particles. According to some embodiments, the molar percentage of additional phospholipids is 35 mol% or less of the particles. According to some embodiments, the molar percentage of additional phospholipids is 25 mol% or less of the particles. According to some embodiments, the molar percentage of membrane-stabilizing lipids is at least 30 mol% of the particles. According to some embodiments, the molar percentage of membrane-stabilizing lipids is at least 40 mol% of the particles. According to some embodiments, the molar percentage of membrane-stabilizing lipids is 70 mol% or less of the particles. According to some embodiments, the molar percentage of membrane-stabilizing lipids is 60 mol% or less of the particles. According to some embodiments, the molar percentage of PEG lipid complex is at least 1 mol% of the particles. According to some embodiments, the molar percentage of PEG lipid complex is at least 1.5 mol% of the particles. According to some embodiments, the molar percentage of PEG lipid complex is 5 mol% or less of the particles. According to several embodiments, the molar percentage of the PEG lipid complex is 3.5 mol% or less of the particle size.

[0525] According to several embodiments, the particles of the present invention are nanoparticles. According to several embodiments, the lipid particles of the present invention are lipid nanoparticles.

[0526] In some embodiments, the particles (including any nucleic acids, therapeutic agents, etc. encapsulated therein, and any target portions bound thereto) have a particle size (diameter) in the range of about 10 to about 500 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 10 to about 350 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 40 to about 270 nm. In some embodiments, the particles have a particle size (diameter) in the range of greater than about 10 nm. In some embodiments, the particles have a particle size (diameter) greater than about 20 nm. In some embodiments, the particles have a particle size (diameter) greater than about 30 nm. In some embodiments, the particles have a particle size (diameter) greater than about 40 nm. In some embodiments, the particles have a particle size (diameter) greater than about 45 nm. In some embodiments, the particles have a particle size (diameter) greater than about 50 nm. In some embodiments, the particles have a particle size (diameter) greater than about 60 nm. In some embodiments, the particles have a particle size (diameter) greater than approximately 70 nm. In some embodiments, the particles have a particle size (diameter) greater than approximately 80 nm. In some embodiments, the particles have a particle size (diameter) greater than approximately 90 nm. In some embodiments, the particles have a particle size (diameter) greater than approximately 100 nm. In some embodiments, the particles have a particle size (diameter) greater than approximately 150 nm. In some embodiments, the particles have a particle size (diameter) of approximately 500 nm or less. In some embodiments, the particles have a particle size (diameter) of approximately 400 nm or less. In some embodiments, the particles have a particle size (diameter) of approximately 300 nm or less. In some embodiments, the size is the hydrodynamic diameter.

[0527] According to several embodiments, the particles further comprise nucleic acids. According to several embodiments, the nucleic acids are encapsulated within lipid-containing particles. According to several embodiments, the nucleic acids are selected from the group consisting of small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA, circular RNA, and immunostimulatory nucleic acids. In several embodiments, the composition further comprises nucleic acids. Examples of nucleic acids include small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA, circular RNA, and immunostimulatory nucleic acids. Each possibility represents a distinct embodiment of the present invention.

[0528] According to several embodiments, the weight ratio between nucleic acids and lipid mixtures may be adjusted to achieve the best biological effect of the nucleic acids at the target site. In some embodiments, the ratio between nucleic acids and lipid phases may be 1:1. For example, the weight ratio between nucleic acids and lipid phases may be 1:2. For example, the weight ratio between nucleic acids and lipid phases may be 1:5. For example, the weight ratio between nucleic acids and lipid phases may be 1:10. For example, the weight ratio between nucleic acids and lipid phases may be 1:16. For example, the weight ratio between nucleic acids and lipid phases may be 1:20. In some embodiments, the weight ratio between nucleic acids and lipid phases is approximately 1:1 to 1:20 (w:w).

[0529] According to some embodiments, the particles further contain a therapeutic agent. According to some embodiments, the therapeutic agent is encapsulated within lipid-containing particles.

[0530] According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein or an immunogenic fragment thereof or a variant thereof. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein, an immunogenic fragment of SARS-CoV-2, or a variant of SARS-CoV-2. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide containing the SARS-CoV-2 spike protein.

[0531] According to several embodiments, the present invention provides a method of gene silencing comprising the step of contacting cells with a composition comprising a plurality of particles and a pharmaceutically acceptable carrier, diluent or additive according to the present invention. In some embodiments, the present invention provides a method of gene silencing comprising the step of contacting cells with a composition comprising the lipids of the present invention. In some embodiments, the cells are cancer cells.

[0532] In other embodiments, the compositions of the present invention may be used as a delivery system for administering a therapeutic agent to a target site in the body. Accordingly, in some embodiments, the present invention relates to a method for administering a therapeutic agent by preparing a composition comprising a lipid and a therapeutic agent as described herein, and administering the composition to a subject requiring it. According to some embodiments, the present invention relates to a method for administering a therapeutic agent by preparing particles as described herein, comprising a therapeutic agent, and administering the composition to a subject requiring it. According to some embodiments, the method further comprises encapsulating the therapeutic agent within lipid-containing particles. According to some embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein, or an immunogenic fragment thereof, or a variant thereof. Each possibility represents a distinct embodiment of the present invention. According to some embodiments, the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein, or an immunogenic fragment thereof, or a variant thereof. Each possibility represents a distinct embodiment of the present invention. According to several embodiments, the therapeutic agent is RNA containing an open reading frame encoding a polypeptide comprising the SARS-CoV-2 spike protein, an immunogenic fragment of SARS-CoV-2, or a SARS-CoV-2 variant. Each possibility represents a distinct embodiment of the present invention.

[0533] In certain embodiments, the present invention provides novel lipids that enable the formulation of improved compositions for delivering IVT-mRNA and / or other oligonucleotides in vitro and in vivo.

[0534] In some embodiments, these lipid nanoparticle compositions are useful for the expression of mRNA-encoded proteins.

[0535] In other embodiments, these improved lipid nanoparticle compositions are useful for upregulating endogenous protein expression by delivering a miRNA inhibitor that targets a single specific miRNA, or a miRNA inhibitor that targets a group of miRNAs that regulate one target mRNA or multiple mRNAs.

[0536] In other embodiments, these improved lipid nanoparticle compositions are useful for downregulating (e.g., silencing) target genes at the protein and / or mRNA levels.

[0537] In some other embodiments, lipid nanoparticles are also useful for the delivery of mRNA and plasmids for transgene expression.

[0538] In yet another embodiment, the lipid nanoparticle composition is useful for inducing pharmacological effects derived from protein expression, such as increased red blood cell production by delivery of suitable erythropoietin mRNA, or protection against infection by delivery of mRNA encoding a suitable antibody.

[0539] In some embodiments, the lipids may be in the form of nanoparticles and may be administered in that form. In some embodiments, the nanoparticles may be administered in solution. In some embodiments, the nanoparticles may be formulated into a suitable pharmaceutical composition to be administered via any desired route of administration. Examples of routes of administration include, but are not limited to, topical, oral, or parenteral administration. Depending on the intended method of administration, the composition used may be in solid, semi-solid, or liquid dosage forms (e.g., tablets, suppositories, pills, capsules, powders, liquids, suspensions, etc.), preferably unit dosage forms suitable for a single dose of a precise amount. The pharmaceutical composition may contain particles, pharmaceutically acceptable additives, and optionally other pharmaceutical agents, medicinal products, carriers, adjuvants, etc. The pharmaceutically acceptable carrier is preferably inert to nucleic acids encapsulated within the particles and does not have harmful side effects or toxicity under the conditions of use. In some embodiments, administration is topical. In some embodiments, administration is systemic.

[0540] In some embodiments, injectable formulations for parenteral administration may be prepared as a solution or suspension, or as a pre-injection solid form suitable for a solution or suspension, or as an emulsion. Suitable additives include, for example, water, saline, dextrose, glycerol, and ethanol. Furthermore, optionally, the administered pharmaceutical composition may further contain small amounts of non-toxic auxiliary substances such as wetting agents or emulsifiers, pH buffers (e.g., sodium acetate, sorbitan laurate monoester, triethanolamine oleate, etc.). Aqueous injection suspensions may also contain substances that increase the viscosity of the suspension (e.g., sodium carboxymethylcellulose, sorbitol, and / or dextran). Optionally, the suspension may further contain stabilizers. Parenteral formulations may be present in sealed containers of one or more doses, such as ampoules and vials, and can be stored in a freeze-dried state requiring only the addition of a sterile liquid carrier (e.g., water) for injection immediately before use. In some embodiments, parenteral administration includes intravenous administration.

[0541] In other embodiments, for oral administration, pharmaceutically acceptable non-toxic compositions may be formed by incorporating any of the commonly used additives (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, croscarmellose sodium, glucose, gelatin, sucrose, magnesium carbonate, etc.). Such compositions include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, and sustained-release formulations. Formulations suitable for oral administration may consist of solutions such as an effective amount of the compound dissolved in a diluent (water, saline solution, or orange juice, etc.); drug sachets, lozenges, and troches (each containing a predetermined amount of the active ingredient as a solid or granule); powders and suspensions in suitable liquids; and suitable emulsions. The liquid formulation may contain water and diluents such as alcohols (e.g., ethanol, benzyl alcohol, and polyethylene alcohols), and may or may not contain pharmaceutically acceptable surfactants, suspending agents, or emulsifiers.

[0542] In determining the dose of particles to be administered, the dose and frequency of administration may be selected based on the pharmacological properties of the specific nucleic acids encapsulated within the particles.

[0543] The lipids of the present invention may be used alone or in combination with other lipid components (such as neutral lipids, charged lipids, steroids (e.g., including sterols) and / or their analogues, and / or lipids complexed with polymers to form lipid nanoparticles for therapeutic agent delivery). In some cases, lipid nanoparticles are used to deliver nucleic acids for the treatment of various diseases or conditions, particularly leukocyte-related conditions (such as inflammation and / or insufficient protein deficiency).

[0544] Accordingly, in some embodiments, the present invention relates to a method for treating leukocyte-related conditions, the method comprising the step of administering a composition according to the present invention to a subject in need thereof. Leukocyte-related conditions may be selected from the group consisting of cancer, infection, autoimmune diseases, neurodegenerative diseases, and inflammation.

[0545] In some representative embodiments, the particles may contain nucleic acids such as siRNA, miRNA, shRNA, and antisense RNA, and may be used in the treatment of various leukocyte-related conditions depending on the type of nucleic acid and specific target leukocyte. In some embodiments, the nucleic acid encapsulated within the particles may be a nucleic acid capable of inducing the silencing of a target gene. In some embodiments, the target gene may be any gene whose expression is associated with the condition being treated. In some embodiments, the target gene may be, but is not limited to, a gene selected from the following: Growth factors (such as EGFR and PDGFR), genes related to angiogenesis (such as VEGF and integrins), and genes involved in intracellular signaling pathways and cell cycle regulation (such as PI3K / AKT / mTOR, Ras / Raf / MAPK, PDK1, CHK1, PLK1, and cyclins). In some embodiments, combinations of nucleic acids, each having one or more targets, may be encapsulated within the particles.

[0546] Examples of leukocyte-related conditions that can be treated with targeted particles according to several embodiments may be selected from, but are not limited to, various cancers, various infections (e.g., viral infections, bacterial infections, fungal infections, etc.), autoimmune diseases, neurodegenerative diseases, inflammation, etc.

[0547] In some representative embodiments, targeted particles containing nucleic acids (such as siRNA or miRNA, shRNA, or antisense RNA) may be used for the treatment of cancer.

[0548] In some embodiments, cancer is a disorder in which a population of cells becomes, to varying degrees, unresponsive to the regulatory mechanisms that normally govern their growth and differentiation. In some embodiments, cancer is a cancer of the blood. Non-limited examples of cancers of the blood include lymphoma, leukemia, and myeloma. Lymphoma may be divided into two categories: Hodgkin lymphoma and non-Hodgkin lymphoma. The majority of non-Hodgkin lymphomas are B-cell lymphomas, which are either rapidly growing (high-grade) or slowly growing (low-grade). There are 14 types of B-cell non-Hodgkin lymphomas. The others are T-cell lymphomas.

[0549] In some representative embodiments, nucleic acids that may be used for cancer treatment target genes related to cell cycle regulation. In some representative embodiments, the target genes may be Polo-like kinase 1 (PLK), cyclin D1, CHK1, or genes of the Notch pathway.

[0550] According to several exemplary embodiments, the lipids of the lipid particles may be naturally derived or synthetic, and may be selected from, but not limited to, cationic lipids, phosphatidylethanolamines, ionized lipids, membrane-stabilizing lipids, phospholipids, and combinations thereof. Each possibility represents a distinct embodiment of the present invention.

[0551] According to some embodiments, the particles further comprise a targetable moiety linked to a component of the composition. According to some embodiments, the particles are complexed with the targetable moiety. According to some embodiments, the targetable moiety may be complexed with any one of the lipids contained in the particles.

[0552] According to several embodiments, the particles may consist of any one or more of the lipids of the present invention, phospholipids (e.g., DSPC), membrane-stabilizing lipids (e.g., cholesterol), and PEG lipid complexes (e.g., DMG-PEG) in various molar ratios, which may be further complexed into the targeting molar, where the targeting molar is complexed, linked to, or attached to any one of the particle components.

[0553] definition For the purpose of aiding the understanding of the present invention, several terms and expressions are defined below. These terms and expressions are for illustrative purposes only, and not intended to limit, so that the technical terms or expressions herein may be interpreted by those skilled in the art in conjunction with any knowledge of the ordinary art present herein, in light of the content and guidance presented herein.

[0554] As...

Claims

1. Chemical formula (II): 【Chemistry 1】 Lipids represented by the structure, R １ However, OH and C １～３ Selected from the group consisting of alkyl-OH, R １３ However, OH, C １～３ Alkyl-OH, C ４～１４ Alkyl and C ４～１４ Selected from a group consisting of alkenils; R １２ is C １～１３ alkyl, C ２～１５ alkenyl, C １～６ alkyl-CO ２ -C1-3 alkylene-N(C １～８ alkyl) ２ , C1-6 alkyl-CO2-N(C1-8 alkyl)2, C １～６ alkyl-CO ２ -C1-3 alkylene-NH-C １～８ alkyl and is selected from the group consisting of C1-6 alkyl-CO2-NH-C1-8 alkyl; R １４ However, C １～１３ Alkyl, C ２～１５ Alkenil and 【Chemistry 2】 Selected from the group consisting of; Each L, L ａ -X ａ -L ｂ It is an alkylene ester linker represented by; X ａ However, -O ２ C-, -CO ２ -C ２～４ Alkylene-O ２ C-, O ２ C-C ２～４ Alkylene-O ２ C-, -CO ２ -C ２～４ Alkylene-CO2 ２ -, and O ２ C-C ２～４ Alkylene-CO2 ２ Selected from the group consisting of: L ａ However, C １～３ Alkylene, C ４～１２ Alkylene, C ２～１０ Selected from the group consisting of alkenylenes and their absence; and L ｂ However, they do not exist, or C1-3 alkylenes, C ２～１０ Alkenylene and C ４～１２ Selected from the group consisting of alkylenes, Lipids.

2. R １ However, OH and C ２～３ A lipid according to claim 1, selected from the group consisting of alkyl-OH groups.

3. R １３ However, OH, CH ２ -OH, and C ４～１２ A lipid according to any one of claims 1 to 2, selected from the group consisting of alkyl groups.

4. R １２ However, C ９～１５ Alkenil, C ５～１１ Alkyl, C ３～６ Alkyl-CO ２ -C1-2 alkylene-N(C ２～８ Alkyl) ２ A lipid according to any one of claims 1 to 3, selected from the group consisting of C3-6 alkyl-CO2-N(C2-8 alkyl)2.

5. R １４ However, C ９～１５ Alkenil, C １～９ Alkyl and 【Transformation 3】 A lipid according to any one of claims 1 to 4, selected from the group consisting of the following.

6. X ａ However, -O ２ C- and -CO ２ -C ２～４ Alkylene-O ２ A lipid according to any one of claims 1 to 5, selected from the group consisting of C-.

7. L ａ However, it does not exist, or C ２～３ Alkylene and C ６～１１ A lipid according to any one of claims 1 to 6, selected from the group consisting of alkylenes.

8. L ｂ However, C １～３ Alkylene and C ４～１２ A lipid according to any one of claims 1 to 7, selected from the group consisting of alkylenes. 【Request Item 9】 【Chemistry 4】 【change】 and 【change】 A lipid according to claim 1, selected from the group consisting of the following.

10. Particles comprising a lipid according to any one of claims 1 to 9 and a membrane-stabilizing lipid, wherein the membrane-stabilizing lipid is selected from the group consisting of cholesterol, phospholipids, kephalins, sphingolipids, and glyceroglycolipids.

11. The particle according to claim 10, further comprising a nucleic acid encapsulated within a lipid-containing particle, wherein the nucleic acid is selected from the group consisting of small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotide, messenger RNA (mRNA), ribozyme, pDNA, CRISPR mRNA, gRNA, circular RNA, and immunostimulatory nucleic acid.

12. A method of gene silencing comprising the step of contacting cells with a composition comprising a plurality of particles according to claim 10 and a pharmaceutically acceptable carrier, diluent or additive.

13. A composition comprising the particles according to claim 10 and a pharmaceutically acceptable carrier, diluent, or additive for treating leukocyte-related conditions.

Images